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CHAPTER 1 
I N T R O D U C T I O N 
Since Lesch and Nyhan in 1964 described two brothers suffering from a 
developmental retardation, cerebral palsy, choreoathetosis, selfdestructive 
behavior, hyperuricemia, hyperuricuria and disturbance of renal function, 
the hereditary, X-linked disease characterized by the afore mentioned symp-
toms has been considered as a nosological entity: the Lesch-Nyhan Syn-
drome, a name proposed by Reed and Fish (1966). Retrospectively it is 
highly probable that Catel and Schmidt ( 1959) and Riley ( 1960) previously 
described children suffering from this syndrome. 
In 1967 Secgmiller et al. discovered a deficiency of the enzyme hypoxan-
thine-guanine phosphoribosyltransferase (HGPRT) in erythrocytes and 
fibroblasts from patients with the Lesch-Nyhan Syndrome. Since this dis-
covery the Lesch-Nyhan Syndrome is defined by all authors as an X-linked 
inherited HGPRT-deficiency with developmental retardation, neurological 
Table I 
CLINICAL FEATURES OF PATIENTS WITH HGPRT-DEFICIENCY 
Symptoms 
Early retardation and hypotonia 
Spasticity 
Dysphagia 
Dysarthria 
Chorcoathetotiform movements and 
opisthotonus 
Selfdestructive behavior 
Renal dysfunction and/or hematuria 
Arthritis and tophi 
Anemia 
Convulsions 
Number of patients 
from which data 
are available 
61 
61 
43 
49 
61 
54 
53 
30 
33 
9 
Number of patients 
in which the 
symptoms are present 
61 
60 
41 
48 
59 
45 
38 
10 
11 
9 
11 
disorders (spasticity and choreoathetosis), bizarre selfdestructive behavior, 
hyperuricemia and occasionally disturbance of renal function and gouty 
symptoms like tophi and arthritis. Some authors reported the occurrence of 
anemia and convulsions. Till now about 120 patients are reported in the 
literature. From 61 patients a rather comprehensive report of the clinical 
features is given (sec table I ) . 
1.1. THE CLINICAL FEATURES 
Van der Zee (1972) gave already a very comprehensive review of the 
clinical features of the Lesch-Nyhan Syndrome. However, it seemed worth-
while to pay more attention to the diversity of the symptomatology. A syn-
opsis of the clinical features of the Lesch-Nyhan Syndrome will be given on 
the basis of the afore mentioned group of 61 patients. This group does not 
include the patients described by van der Zee (1972), whose patients will 
be discussed later on in this work. 
1.1.1. The developmental retardation 
At birth all patients seemed quite normal. Birthweight and -height were 
within normal ranges. Most of the parents did not notice any obvious aberra-
tion in their children until the age of 5 to 6 months. However, retrospec-
tively almost all parents reported that their children sucked poorly and 
impressed floppy. When the patients were about 6 months old most of the 
parents noticed an obvious hypotonia and in all 61 patients gradually a 
retardation in mental and motor development revealed itself. The head 
control was poorly and the children did not learn to sit without support. 
Rolling over was only possible using very intensive exertion and was per-
formed clumsy. Only 3 patients described by Marie et al. (1967), Manzke 
(1967) and Wood et al. (1972) respectively, learned to walk with support. 
The remaining 58 patients were bedpatients or could only move in wheel-
chairs. 
The speech developed late and was described as slurring and dysarthric 
in 48 out of 61 patients. Three patients were younger than 1 year and from 
9 patients no data are available. Only 1 patient developed normal speech 
(Bluestone et al., 1968). The quality of language varied from only a few 
understandable words to the use of several intelligible sentences. The under-
standing of language is much better than the verbal expression and seems 
to be unaffected in most of the patients. 
The intelligence quotients reported in the literature vary from 30 up to 
90% (Michener, 1967). However, all authors made restrictions because of 
the unableness of the patients to perform the verbal and motor parts of the 
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testing procedures. The very low scores in these parts influence the overall 
intelligence quotients in a negative way. All authors agreed that the patients' 
intelligence probably was higher than it seemed to be in a first observation. 
Schcrzer and Ilson (1969) postulated, based on their findings in 1 patient, 
that the mental retardation is a pseudoretardation and they suggested that 
patients with the Lesch-Nyhan Syndrome would score a normal intelligence 
quotient if the testing procedures would be adapted to their specific motor 
and verbal handicaps. Generally, it can be stated that the intelligence is less 
affected than it seems to be in most patients and that the appearance of the 
retarded patient is caused for a large part by his neurological and motor 
disorders. 
The patients' emotional reactions are quite normal. The show adequate 
reactions of happiness, sadness and jealousy. Sociopsychologically all patients 
are described as pleasant and „contact happy" personalities with a certain 
sense of humor. Most of them become the favorites of the nurses because 
of their cheerfulness. This gay and happy state of mind, however, can sud-
denly alter in a state of irritation with a very aggressive behavior of the 
patient against himself or other persons, mostly beloved people like the 
parents or favorite nurses. This aggressive behavior will be discussed later on. 
1.1.2. The neurological symptoms 
Dysphagia is one of the earliest symptoms often reported. This has been 
described in 41 patients. In 2 patients no dysphagia was found and from 
18 patients no data were available. Already since birth the parents com-
plained that the affected children sucked poorly and that food and saliva 
drooled out of their mouth. The patients swallowed their food often in the 
wrong way. A lot of patients vomited frequently in infancy (Sass et al., 
1965; Jeune et al., 1966; Munsat et al., 1968 and Nyhan, 1968 a and b) . 
Hypotonia of the skeletal muscles was described in the first year of life 
in all 61 patients. At the age of about 1 year all patients but one developed 
a spastic quadriplegia but in all these patients the spasticity of the legs ex-
ceeded that of the arms. The deep tendon reflexes were exaggerated and 
in most cases the plantar reflexes were extensor. Frequently, there was a 
spasm of the adductor muscles of the legs resulting in a scissor position. 
These spasms were not persistent; for long periods the patients could be lying 
in bed with a normal or even decreased muscular tonus and than suddenly 
they became hypertonic and spastic, often provoked by noise, attention, pain 
or by the intention of the patient to do or to say something. In the hypertonic 
periods scissor position of the legs, extensor spasms of the arms, neck and 
trunk-muscles and jerks of torsion spasms of arms and trunk could be seen. 
The suddenly occuring choreatiform spasms were also observed when the 
patient was in a state of emotional stress like gayness, sadness or jealousy. 
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Superposed upon these spastic symptoms 59 out of 61 patients showed un-
voluntary movements of a slow athetotic character in the fingers, hands, 
arms, trunk and legs. These movements disappeared when the patient was 
asleep. One child of only 3 months of age and 1 adult did not show these 
symptoms. 
In 9 out of 61 patients convulsions occurred, 7 out of these 9 patients had 
an aberrant EEG. Several authors reported normal EEG registrations in 
their patients without convulsions. One patient was described with seizures 
as the first symptom. Dysarthria, spasticity and selfdestructive behavior 
occurred later and seizures remained to be the major symptom. This patient 
had also an epileptic EEG (Kelly et al., 1972). 
In the cerebrospinal fluid normal values for the concentration of protein 
and glucose and the cell amount were found. Also the concentration of uric 
acid in cerebrospinal fluid was found to be normal (Rosenbloom et al., 1967 
b and c; van der Zee, 1972). 
From several patients a pneumencephalogram had been performed. In 
all cases a slightly symmetrically widened ventricular system had been found, 
according to a mild central cerebral atrofia. These findings were often found 
in combination with a slight cerebellar atrofia. 
Hearing, seeing and eye-movements were unaffected and eye-grounds 
were found to be normal. 
1.1.3. The selfdestructive behavior 
This symptom is the most bizarre and impressing feature in the Lesch-
Nyhan Syndrome. The age of onset varies from 1 year (Sass et all., 1965) to 
14 years (Nyhan, 1968b). In most of ihe patients this behavior reveals itself 
between the second and the nineth year of life and shows a progressive 
character in the following period. The three mostly described forms of auto-
aggression are biting on lips, tongue, jaws and fingers, digging with the 
fingers in the eye-sockets and hitting with head and hands against solide 
objects. This behavior often causes very serious wounds which can become 
infected and may result in destruction of lips, tongue, jaws and even palate 
and nose or in amputation of several digital phalanges. It is not quite clear 
whether the head banging and hitting with the hands is an autoaggressive 
behavior because of the fact that most patients bang and hit also against 
soft objects. It is not excluded that those symptoms just are manifestations 
from the afore mentioned torsion and extensor spasms (see 1.1.2.). During 
this biting and hitting the patients are very distressed and obviously suffer 
from severe pain. The painsensation of the patients in the pinprick test is 
normal and their selfdestructive behavior has a compulsive character. 
It is strikingly that most patients soon became quiet when their hands were 
fastened and their incisive teeth were extracted. After removing of the 
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restraints the patients became very frightened and started pleading for the 
restraints left to be in place and screamed and cried Most of the patients 
showed an individual pattern of biting but, if this pattern was avoided by 
fastening e g one hand it с hanged and the other hand was bitten One 
patient (Nyhan, 1968b) bit only his right hand, his left hand never needed 
to be fastened Occasionally self-induced alopecia was reported as a result 
of autoaggressive hair-plucking (K)han, 1968 b) 
Di7mang and Cheatham ( 1970) studied 5 patients and gave a review of the 
literature as concerning to the selfdestructivc behavior These authors had 
the impression that there was a compulsion to inflict pain and that early 
coincidental pain triggered the compulsion and to some extend it determined 
the site at which injury will continue Developmentally, the lips, the tongue 
and the inside of the mouth are the first areas to be repcatedlv injured and 
the teeth are the instruments of injury At a later age the fingers may also 
become object of injury by the teeth This sequence parallels the develop­
ment of localization and discrimination of touch, pain and pleasure The 
authors suggested a very low threshold for the activation of a mechanism 
that controls repetitive, compulsive, pamcausing behavior 
Verv frequently this aggressive behavior is not only direted towards the 
patient himself but also towards other people in the direct environment 
Mostly the aggression is directed towards beloved people like favorite nurses 
or doctors and towards parents 
A lot of stories are known in which these people have been bitten, hitten 
or pinched This aggression seems to be compulsive too, the patients apology 
immediatel} and feel deeply sorry but at a next occasion they can not avoid 
to do it again Blasphemous language and swearing are well-known mani­
festations of aggression as much in these patients 
An autoaggressive patient is not necessarily aggressive against other people 
too No patient is known who is exclusively aggressive against other people 
and not against himself 
From the afore mentioned group of 61 patients, 45 ones were reported 
to show the selfdestructivc behavior in a degree varying from only a few 
attempts to bite until verv severe repetitive selfinfhctcd injuries In 16 
patients no autoaggressive behavior was seen or repoited However, it is noi 
ver) probably that such a dramatic feature should not be reported if present 
Assuming that those 16 patients did not show the selfdestructivc behavior, 
they can be categorized with respect to their ages as follows From 3 patients 
no age was given in the literature (Shapiro et a l , 1966) From the remaining 
13 patients 9 were younger than 6 years So, it is rather probably that these 
patients would start to mutilate themselves yet One patient was 13('/i2 
years (Nyhan described a patient who started to mutilate himself at the age 
of 14 years) One patient ( M a n e et al , 1967) suffered from severe choreo-
athetosis but showed no selfdestructivc behavior at the age of 16 years I he 
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level of remaining HGPRT-activity is not reported. Two patients without 
self destructive behavior were adults. Bluestone et al. (1968) described a 
man of 24 years old with a decreased HGPRT-activity, hyperuricemia, 
debility of mind, renal function disturbance, arthritis, tophi and anemia. 
There were no signs of choreoathetotiform movements, no spasticity and no 
selfdestructive behavior. Because this patient had a remaining HGPRT-
activity of 1% of the normal value, the authors postulated that they dealed 
with a patient with only a partial HGPRT-deficiency. The absence of self-
destructive behavior might be due to the remaining activity. Munsat et al. 
( 1968) described a 21 years old male with all other symptoms present except 
the selfdestructive behavior. He had a remaining IIGPRT-activity of 5 % 
of the normal value. So, the authors considered him as a patient with partial 
HGPRT-deficiency. It is of interest that in both patients the same method 
of HGPRT-assay has been used (according to Seegrniller et a!.. 1967). Both 
patients did not mutilate themselves but Bluestone's patient with the lowest 
remaining IIGPRT-activity (1%) had a much more milder clinical picture 
than Munsat's patient with a remaining activity of 5%. Furthermore. Mun-
sat described another patient (8··/12 years) with a remaining H G P R T -
activity of 1.5% with the fully developed picture of Lesch-N\han Syndrome 
including selfdestructive behavior. On the basis of these data it can be 
postulated that most of the patients have the selfdestructive behavior but 
not all of them. Furthermore, the existence of a correlation between the 
occurrence of this symptom and the presence of total or partial H G P R T -
deficiency, appears to be doubtful. 
As concerning to the selfdestructive behavior also one of the patients 
described by Michener (1967) is of interest. This patient was an extremely 
retarded spastic boy of 4 years old with choreoathetotiform movements and 
dysarthria, who bit his lower lip in a destructive way. After correction of his 
hyperuricemia by administration of Probenicid this selfdestruction ceased. 
Furthermore, there was a definite improvement of his general well-being. 
Replacement of the Probenecid administration by 4-hydroxypyrazolo 3-4 
pyrirnidine (Allopurinol) did not reveal new periods of autoaggression. In 
all other cases where anti-hyperuricemic drugs were used no influence was 
reported on the selfdestructive behavior. 
1.1.4. The renal dysfunction 
In 38 out of 61 patients there was a history of macroscopic or microscopic 
hematuria or recorded renal function disturbances. All authors agreed that 
the hematuria and the renal dysfunction were the results of a nephropathy 
caused by the hyperuricemia and hyperuricuria which occurred in all 61 
patients. In 15 patients a screening of renal function did not reveal abnor-
malities and no hematuria was found. Detailed studies on tubular function 
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were not performed, except by Larbre et al. ί 1972) who found a disturbance 
of this function аь the first symptom. From the remaining 8 patients, no data 
were available. In all cases disappearance of hematuria and a consolidation 
of the renal function was reported after starting an anti-hyperuricemic 
therapy (Probenecid or Allopurinol). 
Most of the patients showed a remarkable polydipsia and polyuria. Prob­
ably these symptoms were due to the renal dysfunction and have to be 
considered as a result of renal diabetes insipidus. Nyhan (1968b) described 
these symptoms as a kind of self-defence mechanism against the hyper­
uricemia and hypcruricuria. He supposed that the patients protected them­
selves against uric acid stones. These stones occur in fact rather rare in 
patients with hyperuricemia due to HGPRT-deficiency. However, no further 
data could be obtained to affirm this supposition. 
1.1.5. Gouty arthritis and tophi 
From 30 out of 61 patients data about these symptoms are available. Ten 
of them showed both features. The two symptoms were never reported to 
occur singly. From 31 patients no data are available, but because of the 
rather impressing character of these symptoms it is highly probable, that the 
features were not present in these patients. 
T h e gouty arthritis as well as the tophi could be treated very well with 
Probenecid or Allopurinol. 
1.1.6. The anemia 
In 33 out of the 61 patients data are given about the hemoglobin content. 
Eleven of them suffered from an anemia, which had a very grave character 
in some patients, making frequent bloodtransfusions necessary. Kastner 
(1969) reported a slight normochromic anemia. Riley (1960) a severe hypo­
chromic anemia following an abscess and Howard and Walzak (1968) and 
Sass et al. (1965) reported very severe progressive anemias without data 
about the characteristics of the anemias. All other anemic patients (7) 
suffered from a megaloblastic anemia. In the adult patient of Bluestone et 
al. (1968) the anemia was probably caused by a deficiency of folic acid as a 
result of the phenytoin therapy given for prevention of convulsions. After treat­
ment with folic acid the anemia disappeared and did not recur again. In the 
other 6 patients with megaloblastic anemia neither a deficiency of folic acid 
nor a deficiency of vitamin B12 seemed to be the cause of the anemia. Nyhan 
(1968 a and b) and Kelley et al. (1969) reported patients apart from the 
group of 61 patients with megaloblastic anemia. 
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1.1.7. The pathological anatomy 
Few data arc available about pathological anatomy in patients with 
HGPRT-deficiency. From 8 patients an autopsy has been performed 
(Hoefnagel et al., 1965; Sass et al., 1965; Seegmiller. 1968; Crassi et al., 
1969; Storey, 1969 and Crome and Stern, 1972). From these authors 
only Sass and Crussi gave comprehensive descriptions. The other authors 
gave only brief and limited descriptions which agreed with the findings 
of Sass and Crussi. Most comprehensive data are available about the 
findings in the kidneys and the cerebrum. Furthermore, a few authors 
performed a transcutaneous biopsy of the kidney (Marie et al., 1967 and 
Rosenberg et al., 1968). The most impressing findings in the kidneys were 
precipitations of urate with interstitial inflammation, combined with a 
dilatation and atrofia of the tubuli. In patients with a severe renal function 
disturbance a glomerular sclerosis and a thickened lamina media of the 
arteriolae were found. Generally, the pathological picture was that of an 
interstitial nephritis and resembled the picture in patients with gout (Ham­
burger, 1966). 
Sass et al. (1965) described the post-mortem investigations in a patient 
with HGPRT-deficiency who died because of a severe uremia. The brain 
was slightly reduced in size but normal in configuration. T h e frontal sulci 
were slightly widened with mild thickening of the overlying leptomeninges. 
The brainstem and cerebellum were unremarkable with the exception of an 
enlargement of the vallecula cerebelli. The blood vessels were free of athero­
sclerosis and of any anomaly. There was a mild asymmetrical enlargement 
of the lateral ventricles, right larger than left, with mild reduction of the 
central white matter. The overlying cortex was unremarkable. Λ few 
scattered petechiae were noted in the medullar)' cores of dorsal gyri with­
out other gross changes. The basal ganglia, thalamus, brainstem and 
cerebellum were macroscopically normal. Microscopically a lot of vascular 
lesions with hemorrhagias were found in the white matter of cerebrum 
and cerebellum. Furthermore, in the white matter there were zones of 
demyelinization and in the centre some necrosis. In these necrotic areas 
a precipitate, possibly urate, was found. The cerebellum showed a degenera­
tion of the granular cell-layer with the same precipitate. Microscopically 
the basal ganglia were found to be normal. The authors stated that these 
findings agreed with those in the cerebrum of patients who died from uremia 
caused by other diseases. However, they did not exclude that also uric acid 
played a role a.s a cause of the aberrations. Crussi et al. (1969) however, 
described the post-mortem findings in a patient with HGPRT-deficiency 
without uremia and they did not report any aberration. Electronmicroscopic 
investigations have never been reported. 
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In conclusion it can be said that till now in cerebro, no specific patholo­
gical anatomical substrates for the HGPRT-deficiency have been found. 
1.1.8. The diversity of the clinical features 
From the preceding data it can be concluded that there is a wide range of 
manifestations of the clinical features and that the severity of affection 
ranges as much. Ль concerning to the developmental retardation all patients 
are debilitated but next to the extremely deteriorated patients others have 
been described in which the mental deficiency seemed to be of slight or no 
importance. 
Marie et al. (1967) described a patient with a poor development of the 
speech but when he spoke he used two languages, French and Spanish. 
Moreover, he understood both languages and visited schools in both France 
and Spain each a part of the year (Nyhan. 1968b). The neurological symp­
toms, however, in this patient were extraordinary severe. His unvoluntary 
choreoathetotiform movements were so explosive that he was often thrown 
out of his chair. Although he was already 16 years old no sign of self destruc­
tion had ever been observed. 
As concerning to the absence or presence and degree of selfdestructive 
behavior we discussed these aspects in 1.1.3. Nyhan (1968b) already 
revealed that there was no correlation between selfdestruction and the 
presence of a remaining HGPRT-activity. The lower detection limit of his 
assay method was about 0.005% of normal values. He described some 
patients without any detectable activity and other patients with a very low 
but detectable activity (0.009%) who did not mutilate, but as stated before 
(see 1.1.3.) patients have been described with a much higher activity ( 1.5%) 
(Munsat et al.. 1968) who had a severe selfdestructive behavior. Thus, there 
is no correlation between enzymic activity and selfdestructive behavior. A 
correlation between selfdestructive behavior with the serum uric acid content 
could not be demonstrated either (Nyhan. 1968 Ы. The neurological symp­
toms are correlated no more to the HGPRT-activity or uric acid level. 
Spasticity has been found in almost all patients unesteemed the H G P R T -
activity or uric acid level. Choreoathetotiform movements vary from very 
mild (Kästner, 1969; Kelly et al., 1972) to very severe (Marie et al., 1967) 
and can be even absent (Shapiro et al., 1966; Bluestone et al., 1968). 
Since the renal dysfunction and the hematuria can be considered as a 
result of hyperuricemia and hyperuricuria the appearance of those symptoms 
can as much as the appearance of the gouty arthritis and the tophi depend 
on the moment of the start of a therapy. It is strikingly that patients with 
very mild neurological manifestations often have arthritis and tophi but it is 
obvious that in these cases the hyperuricemia or HGPRT-deficiency has 
been diagnosed relatively late. 
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1.1.9. The heredity of HGPRT-deficiency 
Studying the pedigrees of families in which the Lesch-Nyhan Syndrome 
occurs one may conclude that in all probability this syndrome is inherited in 
an X-linked recessive way (Lesch and Nyhan. 1964; Hoefnagel et al., 1965; 
Shapiro et al., 1966; Nyhan et al.. 1967; Rosenberg et al., 1968; Labrune et 
al., 1969; Henderson et al., 1969; van der Zee, 1972). AU patients are maies 
and if there are more patients within one family they are related via their 
mothers. 
Till now no cases are known in which affected males were able to repro-
duce. If this would be possible a patient could mate with a heterozygous 
female and affected females could be born. The same situation might occur in 
Turner's syndrome ( X O chromosomal pattern) but there is no known female 
patient with Lesch-Nyhan Syndrome as well as Turner's syndrome either. 
However, as we pointed out previously (see 1.1.8.) there are adult patients 
with mild symptomatology so that the ability to reproduce is not strictly 
excluded. Another argumentation for the X-linkage of IIGPRT-deficiency 
could be the finding of a coupling of this enzymic defect with other well-
known X-linked properties like G-6PD-cleficiency, color blindness and Xg 
bloodgroup. As a matter of fact Nyhan et al. ( 1970) and Kelly ( 1972) could 
prove the linkage between H G P R T and G-6PD loci on the X-chromosome. 
Furthermore, several investigators (Rosenbloom et al., 1967a; Claassen, 
1969; Salzmann et al., 1968; Migeon et al., 1968; Dancis et al.. 1969b; 
Fujimoto and Seegmiller., 1969 and 1970 and Migeon. 1971) could prove 
that cultured fibroblasts obtained from female heterozygous carriers behaved 
conformably to the so called Lyon-hypothesis. Because of the at random 
inactivalion of the X-chromosome (Lyon 1961, 1962 and 1970) in the 
cultures two types of cells, IIGPRT-positive and HGPRT-negative ones 
respectively, were found. In hairroots from carriers three types of cells could 
be seen; cells without any HGPRT-activity, cells with normal H G P R T -
activity and cells with about half the normal activity, respectively (Gartler 
et al., 1971; Francke et al., 1973; de Bruyn and Oei, 1973). The investiga-
tions on hairroots yield a very suitable method to detect heterozygous carriers 
and to predict the chance on eventual production of an affected child. 
1.1.10 The therapy of patients with HGPRT-deficiency 
As to the treatment of the patient it is obvious that there is no causal 
therapy for the HGPRT-deficiency itself. There is no possibility to supply 
the enzyme to the patient. Several attempts have been performed to influence 
the several symptoms. A lot of authors tried to diminish the severe motor 
handicaps of the patients by means of physiotherapeutic measurements. The 
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results seemed to be poor but no data are available about well-planned 
trainingprograms. 
It is strikingly that in the literature a very fatalistic vision appears as 
concerning to the selfdestructive behavior. Almost all authors consider this 
behavior as obligatory to the syndrome and no attempts have been made to 
influence this behavior with a schedule of sociotherapeutic or behavior-
therapeutic training of the patients However, a lot of authors reported a 
diminishment of the problems if the patient gets in a more favorable condi-
tion because of a loving taking care in an institute for handicapped children 
or by the parents. 
Much better results have been obtained in the treatment of hyperuricemia 
and hypcruricuria. The drug of choice is 4-hydroxipyrazoIo 3-4 pyrimidine 
(Allopurinol) which is a well-known inhibitor of the enzyme xanthine oxi-
dase (see 1.2.2.; fig. 1.). If the conversion of hypoxanthine into xanthine and 
of xanthine into uric acid by means of the latter enzyme is inhibited, the 
production of uric acid decreases (Elion et al., 1966). At the same time the 
amount of hypoxanthine and xanthine will increase but the kidney can 
handle those two components much more easily than uric acid. So, the serum 
level of oxipurines (hypoxanthine and xanthine) will remain low because 
of a good clearance by the kidney (Goldfinger et al., 1965; Klinenberg et al., 
1965). However, the solubility of xanthine in urine is much less than that of 
uric acid, so the danger of formation of xanthine stories during Allopurinol 
treatment is present (Greene et al., 1969). The latter can be avoided by 
alkalization of the urine by administration of sodium bicarbonate. 
In normal individuals administration of Allopurinol results in a reduced 
synthesis de novo of purines but this inhibition can only take place if Allo-
purinol can be converted into its ribonucleotide (Rundles et al., 1963; 
McCollistcr et al., 1964; Krenitsky et a l , 1969b; Elion, 1973). This conver-
sion is catalyzed by H G P R T which is lacking in the patients. In fact no 
inhibition of the synthesis de novo by Allopurinol was found in patients with 
HGPRT-deficiency (Sorensen and Bcnke, 1967; Kelley et al., 1968 and 
Sorensen, 1970). Several investigators tried to inhibit the synthesis de novo 
in the patients by means of azathioprine which is an inhibitor in normal 
individuals and patients with gout (Sorensen, 1966; Kelly et al., 1967b). 
These attempts, however, failed in patients with HGPRT-deficiency because 
of the same reason as mentioned afore for Allopurinol. To exhibit an 
inhibitory effect azathioprine and its metabolites have to be converted at 
first into their ribonucleotides, a conversion catalyzed by H G P R T . 
All anti-hyperuricemic drugs failed to influence the motor condition or the 
behavior of the patients. Only one patient is reported in which the self-
destruction ceased after treatment with the uricosuric drug Probenecid 
(Michener, 1967). 
Ghadimi et al. (1970) found a decreased serum glutamine level in their 
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patient and supposed that this might play a role in the pathogenesis of the 
neurological symptoms. They treated the patient with sodium glutamate and 
a protein rich diet. T h e general condition enhanced indeed but this was only 
a temporary effect. 
Van der Zee et al. (1970) reported a beneficial influence of adenine 
administration on the anemia of the patients. No influence was seen at the 
neurological condition. A comprehensive review of the biochemical mecha­
nism of therapy with adenine on the purine metabolism and its effect on the 
clinical features is given by van der Zee (1972). Schulman et al. (1973) 
found no effect of adenine. The biochemical implications of adenine ad­
ministration will be discussed later on (see З.2.1.). 
Prevention of HGPRT-deficiency is only possible by selective abortion in 
the first weeks of pregnancy if the fetus has been proven to be I I G P R T -
deficient (Fujimoto et al., 1968; Herman et al., 1968; deMars et al., 1969; 
Boyle et al., 1970; Seegmiller, 1970 and van Ileeswijk et al., 1972). 
Summarizing it can be concluded that only the hyperuricemia, the hypcr-
uricuria and the megaloblastic anemia can be fighted successfully. However, 
it is worthwhile to design well-planned schedules for physiotherapeutic, 
sociotherapeutic and psychological treatment to ameliorate the general con­
dition of the patients and to diminish the selfdestructive behavior. 
1.2. THE BIOCHEMICAL FEATURES OF HGPRT-DEFICIENCY 
The most frequently described biochemical aberration in patients with 
HGPRT-deficiency is the hyperuricemia. Already Lesch and Nyhan, (1964) 
postulated that in the patients there was a disturbance in the purine metab­
olism causing an overproduction of the human endproduct of that metab­
olism: uric acid. Before discussing the various aspects of this disturbance it 
seems worthwhile to discuss the normal purine metabolism in man. 
1.2.1. The normal purine metabolism 
Recent reviews concerning the purine metabolism have been given by Seeg­
miller et al. (1963 a. b and c) ; Gutman and Yii, (1965 a and b ) ; Murray 
et al. (1970); Wijngaarden and Kclley (1972) and van der Zee (1972). T h e 
following data have been obtained from these sources if not stated otherwise. 
Uric acid is the physiological endproduct of the purine metabolism in 
man. This compound is useless and has to be removed from the body. T h e 
concentration of uric acid in the serum is the resultant of the synthesis out 
of purines and the excretion by kidney and intestinal tract. Occasionally an 
excess of uric acid can be precipitated in the tissues. The concentration of 
purines is the resultant of the synthesis de novo, the turnover of the nucleic 
acid pool and the exogenous supply of purines (i.e. in the diet) (fig. 2.). An 
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excessively high intake of purines with the diet can cause an increase of the 
serum uric acid level. A part of the excretion of uric acid takes place by the 
intestinal tract (15-25% of the total daily production). The enteral bacteria 
catabolize uric acid ('Wijngaarden and Stetten, 1953; Zöllner. 1969). The 
purine synthesis renal excretion 
nucleic acida purines -H uric acid 
gastrointestinal excretion 
(uncolysis) 
diet precipitation of urates 
Fig. 2 Sources of uric acid and its removal from extracellular fluid. 
rest of uric acid is filtered in the glomeruli of the kidney, but in turn almost 
completely reabsorbed in the proximal tubuli. Finally there is an active 
secretion in the distal part of the renal tubuli (Zöllner, 1969; Steele, 1971). 
Only in abnormal circumstances urate will be precipitated in the tissues i.e. 
in case of a hyperuricemia. 
The synthesis of the purine ring is the result of 10 reactions (fig. 1. and 3.). 
5-phospho-a-D-ribosyl-pyrophosphate (PRPP) plays a key role in the regu-
lation of this synthesis (Fox et al., 1971). PRPP formation takes place by 
phosphorylation of D-ribo.se-5-phosphate by means of ATP. This reaction is 
catalyzed by the enzyme ribose phosphate pyrophosphokinase (PRPP syn-
thetase) : 
D-ribose-5-phosphate + ATP ~* 5-phospho-oc-D-ribosyl-pyrophosphate 
+ AMP 
In a next reaction ß-D-ribosylamine-5-phosphatc is formed from PRPP and 
L-glutamine: 
PRPP + L-glutamine + HoO -* ß-D-ribosylarnine-5-phosphate 
+ L-glutamate + pyrophosphate 
This is the first and rate-limiting step of the purine synthesis. The reaction is 
catalyzed by the enzyme phosphoribosylpyrophosphate amidotransferase. 
This enzyme is subject to a feed-back inhibition by purine nucleotides (Hen-
derson and Khoo, 1965) (fig. 3.). 
In the following reactions the first nucleotide inosine-5-monophosphate 
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(IMP) is synthetized. The following components, namely glycine, formate, 
L-glutamine, CCX, L-aspartate and Λ Τ Ρ participate in this synthesis. 
From IMP an interconversion into other purine nucleotides, nucleosides 
phosphonbosylpyrophosphate-fglutamine 
PRPP amidotransferase —»• I 
-> | <-
adenine 
phosphor ibos-
transferaee 
AMP: 
i-yl-1 adenasi: 
\ a i 
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1 
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Fig. 3. T h e metabolism of purine nucleotides. 
and bases can be realized (fig. 4.). Adenosinc-5-monophosphate (AMP) is 
synthetized from I M P in 2 reactions via adenylosuccinate (S-AMP) : 
IMP + L-aspartate + G T P -» S-AMP + G D P + phosphate 
This reaction is catalyzed by the enzyme S-AMP synthetase and inhibited 
by AMP, the product of the next step, a reaction catahzed by S-AMP lyase: 
S-AMP ^ AMP + fumarate 
AMP can be reconverted into IMP in 1 step catalyzed by the enzyme A M P 
deaminase. This reaction is strongly inhibited by 2,3 diphosphoglyceric acid 
(2,3 DPG) (Askari and Rao, 1968). 
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I M P c a n be c o n v e r t e d i n t o x a n t h o s i n e - 5 - m o n o p h o s p h a t e ( X M P ) by 
m e a n s of the enzyme I M P d e h y d r o g e n a s e a n d X M P in t u r n c a n be con­
ver ted in to g i i a n o s i n e - 5 - m o n o p h o s p h a t e ( G M P ) wi th G M P synthetase as 
t h e cata lyz ing enzyme, L-glutarnine as a m i n o - d o n o r a n d Λ Τ Ρ as energy 
source. G M P c a n be r e c o n v e r t e d into I M P by G M P r e d u c t a s e . T h e m o n o -
p h o s p h o r i b o n u c l e o t i d c s c a n be conver ted in to the i r c o r r e s p o n d i n g di- a n d 
t r i p h o s p h o r i b o n u c l e o t i d e s (fig. 4. a n d 5.) . 
ATP 
ADP < - ^ i A M P 
APRT-ase | adenosine • 
1. 
- adenine 
synthesis de novo 
- S-AMP - ^ | ^тХМР - GTP 
G M P t ^ >GDP 
—»· inosine \HGPRTase( guanoeine 
u ; l u 
hypoxanthine — guanine 
У 
xanthine · 
1 
uric acid 
Fig. 4. The inlerconversion of purine nucleotides, purine nucleosides 
and purine bases. 
T h e p u r i n e nucleot ides exhibi t feed-back inh ib i t ion o n t h e ra te- l imi t ing 
s tep as s ta ted afore. T h e inhib i ted enzyme, p h o s p h o r i b o s y l p y r o p h o s p h a t c 
a m i d o t r a n s f e r a s e has t w o b i n d i n g sites for t h e inhibi tors , o n e for 6-amino-
p u r i n e nuc leot ides a n d t h e o t h e r for 6-hydrox ipur ine nucleot ides (Wijn­
g a a r d e n a n d Ashton, 1959; Caskey et al., 1964) . 
ATP ^=*ADP *=sAMP O M P t * GDP t ^ G T P t\/ 
IMP 
/ \ 
S-AMP XMP 
Fig. 5. Interconversion between mono-, di- and triphosphoribonucleotides. 
T h e p u r i n e nucleot ides c a n be catabol ized to the i r c o r r e s p o n d i n g nucleo­
sides ( a d e n o s i n e , inosine, x a n t h o s i n e a n d g u a n o s i n e ) by t h e m e m b r a n e -
b o u n d enzymes 5-nucleotidases. T h e nucleosides c a n be catabol ized to t h e 
c o r r e s p o n d i n g p u r i n e bases ( a d e n i n e , h y p o x a n t h i n e , x a n t h i n e a n d g u a n i n e ) 
by t h e phosphorylases a c c o r d i n g to t h e following g e n e r a l r e a c t i o n : 
r ibonucleos ide τ p h o s p h a t e -* p u r i n e b a s e + r i b o s e - l - p h o s p h a t e 
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This reaction docs not play an important physiological role in man as 
concerning to adenosine (Huennekens et al., 1 9 J 6 ; Krenitsky, 1967: Krenits-
ky et al., 1968). 
The purine bases in turn can be re-utilized in a salvage pathway for the 
formation of purine nucleotides; adenine can be converted into AMP by 
adenine phosphoribosyltransferase (APRT) and h) poxanthinc, xanthine and 
guanine can be converted into IMP, X M P and GMP, respectively, using 
PRPP as a second substrate, by hypoxanthine-guanine phosphoribosyltrans-
ferase (HGPRT) (fig. 1., 3. and 4.1. 
It is not quite clear if there exist pathways to re-synthetize nucleotides from 
bases via nucleosides. Adenosine is readily converted into AMP by adenosine 
kinase (Caputto, 1962; Bennet et al., 1966; Ho et al., 1968). However, the 
conversion of adenine into adenosine has not been proven to take place in hu-
man tissue. Furthermore, the existence of inosine kinase and guanosine kinase 
to convert inosine and guanosine into I M P and GMP . respectively, is an 
uncertain factor. In conclusion, it can be stated that mainly H G P R T and 
A P R T are the en/.ymes involved in the salvage of purine bases, although 
there are some indications that nucleoside kinases and phosphorylases may 
play a minor role (Broekman and Chumley, 19651. 
From fig. 3. and 4. it appears that there is an interconvension between the 
different groups of purine derivatives. The interconversion between the 
nucleotides has been discussed afore and shown in fig. 4. and 5. Adenosine 
is readily converted into inosine by the enzyme adenosine deaminase (Meys-
kens and Williams, 1971), guanine into xanthine by guanine deaminase and 
hypoxanthine into xanthine by xanthine oxidase. The latter enzyme is also 
responsible for the formation of the endproduct of purine metabolism: uric 
acid. 
1.2.2. The purine metabolism in HGPRT-dejiciency 
The elevated uric acid level in serum of patients with the Lesch-N\han 
Syndrome, the hyperuricuria. and the increased uric acid pool and turnover 
draw attention to the purine metabolism in this syndrome (Lesch and Ny-
han, 1964; Jeune, 1966; Rosenberg et al., 1969 and Sorensen et a!.. 1970). 
Because of the suspicion of a disturbance of the purine metabolism Lesch 
and Nyhan (1964) assayed the incorporation of ^C-glycine into urinary 
uric acid according to the method of Benedict et al. (1952Ì. This incor-
poration is a reliable parameter for the in vivo purine synthesis de novo. 
They found a large increase of the incorporated radioactivity; about 20 times 
that of normal individuals. Hence they concluded that the synthesis de novo 
in those patients is accelerated. Treatment with a/athioprine. in normal 
individuals and gouty patients a well-known inhibitor of the synthesis of 
uric acid, failed to reduce the incorporation of 14C-glycine into urinary 
uric acid (Sorensen, 1966; Seegmiller et al.. 1967). 
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Cultured skin fibroblasts from normal individuals are inhibited in their 
growth by 6-mercaptopurine. Fibroblasts of the patients, however, were 
resistent to this inhibition. Broekman (1965) found a similar phenomenon 
in a line of carcinoid cells and discovered a deficiency of I IGPRT in these 
cells. 6-Mercaptopurine has to be converted into its ribonucleotide by this 
enzyme in order to express its growth inhibiting capacity. With reference to 
these investigations Seegmillcr et al. (1967) assayed the HGPRT-activit) 
in erythrocytes of the patients and discovered that there was no activity. 
Later on the deficiency was also found in the basal ganglia and the liver 
(Rosenbloom et al., 1967 a, b and c; Kelley. 1968; Boyle et al.. 1970; van 
Heeswijk et al., 1972), in lymfocytes (Brown et al., 1968; Dancis et al., 1968) 
and in skin, testis, spleen and kidney cells (Boyle et al., 1970; van Heeswijk 
et al., 1972). Dancis et al (1969a) , found the deficiency in immature 
erythrocytes. Also in amniotic fluid cells and fetal tissues the enzyme defi-
ciency was found (Fujimoto et al., 1968; deMars et al., 1969; Berman et 
al., 1969; Boyle et al., 1970; van Heeswijk et al., 1972). 
1.2.2.1. The IIGPRT-deficiency 
After the discovery of the HGPRT-deficiency by Seegrniller et al. ( 1967) 
several authors assayed the HGPRT-activity in their patients with the typical 
features of the Lesch-Nyhan Syndrome. In the first publications always an 
absolute absence of activity has been reported (Ghadimi et al., 1970: Sper-
ling et al., 1971). This absolute deficiency distinguished these patients with 
the Lesch-Nyhan Syndrome from a group of patients with X-linked heredi-
tary primary gout with no or only mild neurological symptoms. In the latter 
group only a partial deficiency with a detectable remaining HGPRT-activity 
varying from 0.03-30% of normal activity was found (Minzuno et al., 1970; 
Sorensen, 1970; Sperling et al., 1971). However, Munsat et al. (1968) 
previously reported a patient with spasticity, choreoathetosis and selfdestruc-
tivc behavior with a remaining activity in the erythrocytes of 1.5% of the 
normal value. Labrune et al. (1968 and 1969) described a patient with the 
Lesch-Nyhan Syndrome, who showed a IIGPRT-activity in the crythocytes 
of 4 % of normal. However, this observation is questionable because it 
represents the activity found in a patient after a bloodtransfusion. The re-
maining activity might be due at least partly to the presence of donor 
erythrocytes in the blood of the patient. Later on, more sensitive assay-
methods have been developed. In fibroblasts and erythrocytes of patients 
with the Lesch-Nyhan Syndrome small but measurable HGPRT-activities 
have been detected varying in a range of 0.001-0.79% of normal values 
(Fujimoto and Seegrniller, 1970; Kelley and Wijngaarden, 1970; Kelley and 
Meade, 1971; Sorensen, 1970; Sorensen et al.. 1970; Chow et al., 1970; 
Migeon, 1970; McDonald and Kelley, 1971; deMars, 1971 and Arnold ct 
al.,'1972 a and b) . 
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The finding of this remaining enzymic activity offered the possibility to 
investigate the properties of the mutant enzyme. These studies revealed, that 
in some cases the mutant enzyme had a decreased heat-slability in com-
parison with the normal enzyme (Kelley and Meade, 1971). In addition 
Arnold et al. (1972 a and b) found in 2 of the patients with a decreased 
heat-stability of H G P R T and in some other patients an accelerated half-life 
of the enzyme in circulating erythrocytes. Furthermore, there were different 
kinetic properties between the normal and the mutant enzyme as well as 
between the mutant enzymes obtained from patients with the Lesch-Nyhan 
Syndrome out of different families. McDonald and Kelley (1971) reported 
a case of a remaining IIGPRT-activity of 0.79% of normal. This patient 
suffered from the typical Lesch-Nyhan Sydrome. The mutant enzyme ob-
tained from this patient's erythrocytes showed clearly altered kinetic proper-
ties. Normally, the PRPP substrate curve had a hyperbolic shape (Hender-
son et al., 1968; Krenitsky et al., 1969b) and only at very low ratios of the 
concentrations of M g + + to PRPP the enzyme exhibits sigmoidal kinetics. 
However, the mutant enzyme exhibited sigmoidal kinetics in all circum-
stances. In addition the Michaelis constant for both guanine and hypoxan-
thine was 13 times that of the normal enzyme. Using a high concentration 
of PRPP the specific activity of the mutant enzyme increased up to 34% 
of normal activity with hypoxanthine as a substrate. Kelley and Meade 
(1971Ì found the enzyme in one of their patients to be insensitive to end-
product inhibition by I M P and G M P in contrast with H G P R T of normal 
individuals or other Lesch-Nyhan patients. Some authors investigated the 
electrophoretic properties of H G P R T (Bakay and Nyhan, 1971 and 1972) 
and found definite differences. They found two mutant enzymes, one moved 
electrophoretically 15% faster and the other 12% faster, through the gel-
column than the normal enzyme. 
Protein content of purified enzyme extracts from deficient patients was 
identical to that of normal individuals and immunochemically there was 
no difference between normal and mutant enzyme (Rubin et al., 1971; 
Arnold et al.. 1972 a and b; Kaiser et al., 1973). Kelley et al. (1969) proved 
that several other physical properties like molecular weights and pH-optima 
of normal and mutant enzyme are identical. 
In conclusion it can be said that the mutation in HGPRT-deficiency is 
usually, if not always, on the structural gene coding for this enzyme and 
furthermore, there is genetic heterogeneity between the different patients 
with HGPRT-deficiency. 
1.2.2.2. The purine synthesis de novo in HGPRT-deficiency 
Lcsch and Nyhan (1964) investigated for the first time the purine syn-
thesis de novo in patients with HGPRT-deficiency in vivo. They used a 
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method previously applied by Benedict et al (1952) in patients with gout 
1 4C-glycine is incorporated into the purine nngstructure The amount of 
incorporated 1 4C-gl)cine in u n n a n uric acid is a measure for the rate of 
purine synthesis de novo A detailed description of this method and its 
application in two of our patients has been g;iven bv van der Zee et a l , 
(1970) and van der Zee, (1972) All authors found a large increase of the 
incorporated 1 4C-gl>cine into urinary uric acid calculated tumulatively in 
the 7 days following the oral gift of 14C-glycine (20 times the normal values, 
Lesch and Nyhan, 1964) 
Rosenbloom et al ( 1968 a and b) detected an increase of purine synthesis 
de now in cultured skin fibroblasts of patients with H G P R Г-deficiency 
From these findings it can be concluded that one of the factors responsible 
for the hyperuricemia is the overproduction of uric acid caused by the 
increased purine synthesis 
Generally, it has been accepted that the increase of purine synthesis de 
now in HGPRT-deficient individuals is due to a decreased feed-back inhibi­
tion Because of the findings of Holmes et al (1973) that the rate-limiting 
en¿yme exposed to feed-back inhibition the phosphonbosylpyrophosphate 
amidotransferase (see 12 2 ) is as sensitive to inhibition by nucleotides in 
HGPR I -deficient cells as in normal ones, the decreased inhibition probably 
results from alteiations in the concentrations of the inhibitors 
12 2 3 The interconversion of purine derivatives m HGPRT-defu lency 
Our findings concerning purine nucleotide concentrations in erythrocytes 
draw our attention to the interconversion of purine derivatives (Lommen 
et al , 1971 ) (fig 4 ) On the basis of the aberrant purine nucleotide pattern 
(decreased adeninenucleotides, see 3 2 1) in our patients' erythrocytes we 
suggested the existence of a shift from adenine nucleotides towards I M P 
and the guanine nucleotides in patients with HGPRT-deficiencv (Lommen 
et a l , 1971) The finding of Pehlke et al (1972) that I M P dehydrogenase 
activity in erythrocytes of patients with HGPRT-deficiency was increased 
might be a support for this hypothesis just like the results of experiments 
performed bv Raivio and Seegmiller, (1973) They incubated fibroblasts 
with '- 'C-ademne In normal fibroblasts about 2 % of all radioactivity was 
recovered in the guanine nucleotides However, in H G P R T deficient fibro-
blasts those nucleotides contained about 5 % of all radioactivity The path-
way that was followed was adenine -» AMP -» I M P —* X M P —' G M P 
Those results could be interpreted as an additional indication for the 
existence of a shift of AMP via I M P and X M P towards G M P The bio-
chemical aspects of this shift will be discussed later on (see 3 2 1 and 3 2 4 ) 
Balis ( 1968) and Sorensen ( 1970) called attention to a consequence of the 
HGPRT-deficicnc v, namely its effect on the interconvcrsion of purine den-
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vatives They postulated that H G P R T completes the sequence of reactions 
in a cyclic interconversion of adenine and hypoxanthinc d e m a t n e s and that 
a deficiency oí the en / \me results in a depletion of intracellular adenine 
nucleotides (fig 3 and 4 ) This theory was supported by the findings of 
Raivio and Seegmiller, (1973) that in contrast with normal fibroblasts 
being able to convert 38 rf of »•iC-h\pc xanthine via I M P to AMP, H G P R l -
deficient cells did not show this conversion and thus \ M P will leak awa\ 
via adenosine ^ inosine ~* hvpoxanthine ""* xanthine and uric acid (fig 3 
and 4 ) 
The existence of an inosine kinase or guanosine kinase actmty in HGPRT-
deficicnt cells is quite uncertain Broekman and Chumley (1965) postulated 
the presence of these enzymic actrwties in HGPRl-deficient tumor cells 
because of the inhibiting effect of those nucleosides on the purine svnthesis 
de now Contradictory results as to the presence of inosinase kinase activity 
in tells from Les^h-IWhan patients ha \e been reported bv Friedman et al 
( 1969) who did not find any ac tivitv in fibroblasts and by Payne et al ( 1970) 
who obtained evidence for the existence of inosine kinase in HGPRT -defi-
cient leucocytes However, Raivio and Seegmiller (1973Ï could not demon-
strate am inosine kinase activity in HGPR Г-deificient fibroblasts It is not 
excluded that the afore mentioned conversions of nucleosides into nucleotides 
result from a preceding conversion to purine bases followed by the synthesis 
of nucleotides by a very low remaining activity of HGPRT 
No differences have ever been reported in the enzymes adenosine deami­
nase or A M P deaminase from HGPRT-deficient cells and normal ones 
Several authors however reported an increase of the activity of APR Γ in 
H G P R Г-deficient erythrocytes ÍSeegmiller et al , 19Ь7, Kellev et al , 1967 а 
1969, Kelley, 1968, Henderson et al . 1969, Sorensen, 1970, van der Zee et 
a l , 1970, van der Zee, 1972^ I his increased activity is coupled with an 
increased heat-stability of the enzvme (Henderson et al , 1969, Kelley et al , 
1969, Greene et a l , 1970) and a dclaved half-life (Rubin et al 1969) 
However, this increase of activity was not always found in H G P R I -deficient 
fibroblasts Possibly the alterations are not due to genetically determined 
structural changes but to altered circumstances in which the APR Γ has to 
exhibit its activity (Kelley and Wijngaarden 1970, Kellev et al 1971b) 
Possibly the increase of APR Г-activity in erythrocytes is caused by the 
decrease of the concentrations of adcninenucleotidcs which exert a product 
inhibition on A P R T ( H o n and Henderson 1966, Lommen et al 1971) 
1 3 THE RELATIONSHIP BETWEEN BIOCHEMICAL ABERRATIONS AND 
CIINICAL FFAIURFS 
As far as concerning the renal dysfunction and the gouty symptoms the 
relationship with the hyperuricemia is quite clear With respect to the other, 
especially the neurological symptoms and the Ьігагге behavior however a 
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possible relationship still remains a mystery. Van der Zee (1972) gave a 
comprehensive review on the hypotheses concerning the nature of toxic 
substances in HGPRT-deficiency. It seems to be unlikely that uric acid. 
hypoxanthine or xanthine would cause the neurological features because 
other diseases characterized by high concentrations of these substances (gout, 
xanthinuria) are not necessarily coupled with neurological symptoms. The 
lack of H G P R T itself has Ъгеп discussed too in this connection because of 
the presence of a very high activity of H G P R T in normal brain tissue and 
the absence in Lesch-Nyhan Syndrome (Roscnbloom et al., 1967 b and c) . 
However, from the preceding (see 1.1.3. and 1.1.8.) it can be seen that there 
is no definite relationship between the severity of the symptoms and the level 
of remaning HGPRT-activity in erythrocytes. No data are available about 
remaining activity in brain tissue of different patients. 
Geerdink et al. (1973) described a patient, an adult male with gout and 
only slight neurological symptoms with a total HGPRT-deficiency. Pre­
viously (see 1.1.З.), we discussed already some patients with severe self-
destruction but detectable HGPRT-activity. 
The findings of Benke and Herrick (1972) and Etienne et al. (1973) 
cast some doubt on HGPRT-deficiency as the cause of all symptoms, too. 
They described each a male with overproduction of uric acid, borderline 
normal intelligence, spasticity, choreoathetosis and selfdestructive behavior. 
However, these patients had quite a normal H G P R Г-activity. The defect 
in these patients is an accelerated purine synthesis de novo. Van der Zee 
(1972) supposed that one of the causal factors in symptomatology is a 
disturbance of the synthesis of nucleic acids causing already before birth an 
irreversible braindamage and post-natally the megaloblastic anemia. An­
other cause for the megaloblastosis could be the therapy with Allopurinol, 
interfering with pyrimidine synthesis (Fox et al., 1970, 1971; Kelley and 
Beardmore, 1970; Kelley et al., 1971 a; van der Zee, 1972). 
In conclusion it can be stated that the relationship between biochemical 
aberrations and clinical features in HGPRT-deficiency has not been eluci­
dated. 
T h e uncleamess about the cause of symptomatology is of course one of 
the reasons that all efforts fail to apply a drug therapy for HGPRT-defi­
ciency which is efficacious on all symptoms. 
1.4. SCOPE AND PURPOSE OF THE PRESENT INVESTIGATIONS 
The present investigations aims at a new contribution to the relationship 
between the most remarkable biochemical aberrations of the Lesch-Nyhan 
Sydrome, namely the HGPRT-deficiency and the accelerated purine syn­
thesis de novo. The primary purpose of the study was to establish the role of 
purine nucleotides, especially the monophosphates, being the products of the 
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HGPRT-cdtalyzcd reaction, because of their key position in the regulation 
of the purine metabolism Furthermore, the confrontation with patients 
without any detectable HGPRT-activity but clinical features which differ 
completely from the Lesch-Nvhan Syndrome yielded new possibilities to 
study the eventual relationship between biochemical and clinical features 
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CHAP TER 2 
CLINICAL FEATURES O F T H E OWN PATIENTS 
2.1 PATIENTS WITH THE TYPICAL SYMPTOMS OF THE 
LESCH-NYHAN SYNDROME 
The first two patients A, and A^ have been reported already comprehen-
sively by van der Zee (1972) as his patients I I 3 and I I j , respectively. There-
fore, as concerning to these patients this report will be limited to a summary 
of the findings of van der Zee, supplied with recent findings and observa-
tions. An older brother of these patients (patient 11) as coded by van der 
Zee) suffered from severe mental and motor retardation, choreoathetosis, 
renal dysfunction and selfdestructive behavior. The cause of these symptoms 
was never found. This boy died suddenly without any diagnosis. 
2.1.1. Patient A, 
The patient was born August 3rd., 1959. Pregnancy and delivery were 
unremarkable. Birthweight and -height were within normal ranges. His 
development was undisturbed until the age of 5 months when the parents 
noticed a retardation in the motor development and a hypotonia. At the 
age of 9 months he visited our clinics for the first time. He was not able 
to roll over or to sit without support. There was a severe hypotonia. He did 
not grasp for objects. The symmetric and asymmetric tonic neckreflexes were 
still present. Deep tendon reflexes were symmetrically exaggerated and the 
plantarreflexes were extensor. The latter signs pointed to a spastic diplegia 
of the legs. At the age of 13 months the patient was admitted to our clinics 
because of ulcerous defects on his lower lip and his thumb as a result of his 
compulsive biting. Painsensation seemed to be intact. There was an obvious 
dysphagia and the muscular tonus was increased. There was even a hyper-
tonia now. Periods of extensor spasms and choreoathctotiform jerks were 
observed. A megaloblastic anemia was found and the urinary sediment con-
tained a large amount of uric acid crystals. Cerebrospinal fluid did not 
reveal abnormalities. No investigations on renal function were performed. 
In the following years the choreoathctotiform movements increased. Tor-
sion spasms of trunk, arms and legs occurred and at the age of 2(i/12 years 
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Table II 
LABORATORY FINDINGS OF P A T I E N T Ai 
Serum urea 
Serum creatinine 
Serum uric acid 
Urea clearance 
Creatinine clearance 
Max spec weight of urine 
Max osmolality of urine 
Urinary pH after NH-iCl load 
Hemoglobin 
Mean Corpuscular Volume (MCV) 
Age (years) 
(m - Ί ' / Ι ) 
(μηιοΐ/ΐ) 
(mmol/1) 
(ml/m i/l 73 m a ) 
(ml/min/l 73 in 2 ) 
(mosmol/kg) 
(mmol/1) 
(fl) 
Before treatment with 
Mlopurinol and adenine 
4 
8 3-9 4* 
78-112 
— 
10-14 
30-36 
1010 
— 
—. 
4 5-6 6 
143-165 
9 
8 0-9 9 
r)4-63 
0 52-0.70 
22-25 
45-60 
1 013 
364 
—. 
5 1-5 6 
147-153 
During treatment 
Allopurinol and 
9 
8 0 
74 
0 18 
16-21 
52-63 
1 013 
446 
— 
7 8 
94 
11 
8 1 
57 
0 18 
17-21 
50-63 
1013 
408 
5 6 
8 0 
108 
ad 
with 
emne 
13 
100 
76 
0 16 
20 
60 
1 013 
423 
5 6 
8 3 
117 
* If two values are gi\en, these represent minimum and maximum values 
the patient was not able to speak. At (he age of 3 years the patient was 
stroken by a convulsion. His selfdestructive behavior made extraction of 
all his milk-teeth and fastening of his arms necessary. At the age of 4 years 
he was admitted to the clinics again. Now he spoke some words but in a very 
dysarthric mode. He was very aggressive towards his nurses and he bit and 
swore. The megaloblastic anemia was more severe now. No deficiency of 
folic acid or vitamin 1312 was found. 
There was a disturbance of renal function; the glomerular as well as the 
tubular function were affected. In the following years no new aspects became 
available. Several electroencephalograms showed various aberrations and 
since the age of 7 years there were signs for a focus in the left occipital area 
(Dr. J. B. Krijgsman). As a therapy the patient received phénobarbital and 
diazepam. Vitamin B12 and folic acid administration did not influence the 
anemia. 
At the age of 9 years at a new admission the patient appeared to be much 
to light and to short for his age. He was a rather pleasant person now who 
spoke some small intelligible sentences. Speech, however, was still dysarthric. 
He recognized his nurses and called them with their names. Furthermore, 
he showed a certain sense of humor. Suddenly, however, he might become 
very angry. Teeth had to be extracted to avoid biting. The neurological 
findings were identical to those at the age of 4 years: spastic diplegia of the 
legs, unvoluntary choreoathetotiform movements, extensor and torsion 
spasms of arms, legs and trunk and frequent head-banging. The renal func-
tion was still diminished. At this age the first assay of serum uric acid con-
centration was performed. An increased concentration was found: 0.70 
mmol/1 (normal value: 0.24-0.32 mmol/l). 
The diagnosis Lesch-Nyhan Syndrome was postulated. The finding of the 
deficiency of H G P R T affirmed the diagnosis. The patient received now a 
therapy consisting of Allopurinol in a daily oral dosage of 10 mg/kg body-
weight (to reduce the serum uric acid level) and adenine in a daily oral 
dosage of 20 mg/kg bodyweight. The effect of this therapy on the clinical 
and biochemical features was discussed by van der Zee (1972) and can be 
summarized as follows: There was a definite improvement of the anemia. 
The renal function remained dimished but was stable. No influence of the 
therapy on the selfdestructive behavior or the neurological symptoms was 
observed. 
At the age of 13 years the patient was admitted again for observation. 
At that moment the patient received the therapy of adenine and Allopurinol 
already 4 years. The hemoglobin content was still normal but the erythro-
cytes were larger again, perhaps because of the influence of Allopurinol on 
pyrimidine biosynthesis (van der Zee, 1972). The renal function remained 
constantly diminished. As concerning to the neurological symptoms a com-
prehensive investigation (Dr. J. Korten, Department of Neurology) revealed 
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Table III 
LABORATORY FINDINGS OF PATIENT Aa 
Before treatment with During treatment with 
Allopurinol and adenine Allopurinol and adenine 
Scrum urea 
Serum creatinine 
Serum uric acid 
Urea clearance 
Creatinine clearance 
Max. spec, weight of urine 
Max. osmolality of urine 
Urinary pH after NH-iCl load 
Hemoglobin 
Mean Corpuscular Volume (MCV) 
(μιηοΐ/ΐ) 
(mmol/1) 
( mrnol/l ) 
(ml/min/1.73 
(ml/mm/1.73 
(mosmol/kg) 
( mmol/1 ) 
(fi) 
Age (years) 
m··
1) 
m
2 ) 
«/» 
6.4-7.0* 
42-46 
0.49-0.58 
14-17** 
47-53 
— 
--
— 
8.6 
9Ü 
2 
6.9-7.4 
39-42 
0.53-0,62 
28-41 
45-59 
1.022 
640 
— 
7.2-8.1 
108-112 
2 
4.3 
44 
0.26 
32-40 
61-74 
1.020 
630 
- -
7.3 
101 
4 
6.0 
54 
0.24 
35 
60 
1.020 
620 
5.3 
7.6 
91 
G 
8.0 
60 
0 26 
28 
72 
1.015 
546 
6.2 
9.2 
101 
* See table II 
** in ml/min/m2 
a quadriplcgia spastica most expressed in the legs combined with a hypo-
tonia suggesting a lesion of the descending s)stems which inhibit the spinal 
posterior horn, possibly a lesion of the paneto-ponto-spinal systems Further-
more, the patient showed uncontrolled movements as signs of a loss of recip-
rocal inhibition especially in the muscle groups controlled by the extra-
pyramidal systems This gave the movemenis an athetotic-balhstic aspect 
These facts do not justify the conclusion that those signs were the result of a 
lesion exclusively of the stnatary systems Furthermore, the extreme spasm 
of the leg adductors could plead for a lesion of the cerebellum An elec-
tromyogram (EMG) revealed a normal nerve conduction time but a slight 
facilitation of the H-response 
A review of the laboratory findings of the patient A] is given in table II 
2 1 2 Patient A¿ 
This patient is a brother of patient Aj He was born March 14th , l%b 
His case history is almost identical to that of his brother Aj There is only 
a slight difference m the age of onset of the symptoms Treatment with 
adenine and Allopurinol yielded similar results (van der Zee, 1972) A 
review of the laboratory findings in patient A, is given in table I I I 
The patient stays in the institute for handicapped children „Huize de 
Winckelsteegh", Nijmegen Since april 1973 he is treated according to a 
behavior-therapeutic training program directed towards his self destructive 
behavior 1 he outline, purposes and first results of this treatment will be 
reported bv Duker (1973) The basic principles are a positive attitude of the 
therapeutist when the patient is quiet and to ignore the patient when he is 
crying or tries to bite himself The therapeutist only takes care that the 
patient does not hurt himself in a disastrous way The first results of this 
therapy are very hopeful The moments in which the patient tries to bite 
himself have been reduced within a few months to almost /его T h e patient 
needs not longer to be fastened to avoid bitmg His mood is ameliorated It is 
stnkinglv that the head-bangmg did not diminish This fact confirms per­
haps the supposition, that the head-bangmg is not a manifestation of self-
destructive behavior but possibly a result of the extensor and torsion spasms 
(sec 1 1 3 ) It seems worthwhile to continue this training program with this 
patient and to apply it on other patients too, when there is more comprehen­
sive experience about it 
2 1 3 Patient В 
As far as we know, this patient is not related to any other patient described 
here Several of his maternal uncles suffered from severe spasticity, choreo-
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athetosis and selfdestructive behavior and died as a result of renal dysfunc­
tion * 
Patient B, a boy, was born Januar) 7th 1971 Since the age of about 
10 weeks the parents noticed a retardation in mental and motor develop­
ment Therefore, he was admitted to the „St Clara Hospital" Pediatric 
Department (Head Dr Warmolts, pediatrician), Rotterdam, the Nether­
lands J η the following months he developed the clinical picture of the 
Lesth-Nvhan Syndrome with choreoathetotiform movements, mental retar­
dation, lip-biting, hyperuricemia, uncaciduna, megaloblastic anemia and 
Table IV 
LABORATORY FINDINGS OF PATIENT В 
Serum urea 
Serum creatinine 
Serum in ic a u d 
Urea clearance 
Creatinine clearance 
Max spec weight of urine 
Max Obmolality of urine 
Age (years) 
(mmol/1) 
(μπκ>1/1) 
(mmol/1) 
(ml/min/m'-2) 
(ml/min/1 73 m 2 ) 
(mosmol/1) 
Urinary pH after NHiCl load 
Hemoglobin 
Mean Corpuscular Volume 
(mmol/1) 
(MCV) (fl) 
Before 
treatment 
with 
Allopurinol 
and adenine 
Ίη 
8 4 
57 
0 7 1 
11 5-16 5* 
50 66 7 
1 Oil 
444 
6 6 
6 6 
95 
During 
treatment 
with 
Allopurinol 
and adenine 
IVu 
( ) 4 
51 
0 24 
18 6-19 4 
131-144 
1 013 
487 
4 7 
7 3 
93 
* See table II 
spastic paresis of the legs There was a disturbed balance between the pro­
prioceptive input and the motor response on this input pointing to a 
pyramidal disorder (Dr J Korten, Department of Neurology ) 
At the age of 7 months he was admitted to the Pediatric Department of 
the University of Nijmegen We assayed the HGPRT-activitv in the erythro­
cytes Using a modification of the method of Cartier and Hamct ( 1 % 8 ) , 
no activity was detectable Using a more sensitive unpublished modification 
of the method of Harris and Cook (1060) an епгутіс activity of 3 nmol/mg 
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protein/h was found (normal values: 77 ± 17 nmol/mg protein/h) with 
hypoxanthinc as substrate (see table V'III) . After treatment of the patient 
with Allopurinol (a daily dosage of 20 mg/kg bodyweight) serum uric acid 
concentration normalized. In view of our experience with two other patients 
with the Lesch-Nyhan Syndrome (Patients A, and AL>) we treated the 
patient since 7 months of age orally with adenine, in a daily dosage of 
20 mg/kg bodyweight. As a result of this treatment the megaloblastic anemia 
improved. 
For several months the patient was in a rather good condition with a 
normal renal function and normal hematological findings. At the age of 
2 years he died suddenly at home by accidental suffocation (as a result of the 
dramatic circumstances of his death, no autopsy was carried out) . 
Table IV gives a review of the laboratory findings in this patient. 
2.2. PATIENTS WITH A SYMPTOMATOLOGY ATYPICAL FOR THE 
LESCH-NYHAN SYNDROME 
2.2.1. Patient Cl 
As far as we know, patient C , is not related to the patients Aj , A2 or B. 
He was born September 1st., 1968. His parents, brother and 2 sisters are in 
good health. Two maternal uncles (one of them is patient C¡); see 2.2.2.) 
suffered from gouty arthritis, hyperuricemia, mild mental deficiency and 
dysarthria. Pregnancy and deliver)' were quite unremarkable. The parents 
did not notice any abnormality in the development of their child in the first 
9 months of life. Then gradually, the boy showed an obvious retardation in 
his mental and motor development. 
The patient started to talk at the age of 1 year but the development of 
his language was delayed. He started to walk at the age of 2('/1;> years and 
developed a tiptoe walk. 
After establishment of the HGPRT-deficiency in his uncle's erythrocytes 
(Patient Co) the patient was admitted to our clinics in order to investigate 
whether patient C | also showed this enzyme deficiency. At the moment of 
admission we saw a boy of 4'1/12 years old with normal bodyheight and 
-weight. The investigations revealed a hyperuricemia, hypcruricuria, a slight 
spastic diplegia of the legs and a slightly decreased renal function which 
seemed to be caused by a diminished tubular function. His mental age was 
estimated at about 2( i/i2 years. There was no megaloblastosis, anemia, 
choreoathetosis or autoaggressive behavior. HGPRT-activity was not detec-
table in erythrocytes neither in the Cartier-modification, nor in the Harris-
modification (see table V I I I ) . He left our clinics with a treatment of Allo-
purinol in a daily dosage of 15 mg/kg bod)weight in two oral gifts. Further-
more, he received intensive physiotherapeutic training. 
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After 1 month serum und urinary uric acid values were within normal 
ranges and there was a remarkable improvement of his walking pattern and 
motor behavior, probably caused by the physiotherapy. An ambulatory inves­
tigation 3 months later, revealed a further improvement, also in his social 
behavior. 
A review of the laboratory findings in patient C) is given in table V. 
Table V 
LABORATORY FINDINGS OF PATIENT Ci 
Before 
treatment 
with 
Allopurinol 
During 
treatment 
with 
Allopurinol 
Age (years) 4'/12 410/,. 
Serum urea (mmol/l) 
Serum creatinine (μηιοΐ/ΐ) 
Serum uric acid (mmol/l) 
Urea clearance (ml/min/1.73 m s ) 
Creatinine clearance (ml/min/1.73 m'2) 
Max. spec, weight of urine 
Max. osmolality of urine (mosmol/kg) 
Urinary pH after NHiCl load 
Hemoglobin (mmol/l) 
Mean Corpuscular Volume (MCV) (fl) 
7.0 
52 
0.81 
30-40* 
75-85 
1.021 
647 
5.3 
7.7 
85 
5.6 
45 
0.24 
--
— 
-
8.4 
92 
* See table II 
2.2.2. Patient C2 
This patient is an adult male 32 years old. He is a brother of the mother 
of patient C ) . Since several years he was known as a patient with a here­
ditary' hyperuricemia, gouty arthritis, mild mental deficiency and dysarthria. 
Hematologically there was a slight megaloblastosis but no manifest anemia. 
Very intensive investigations did not reveal choreoathetosis or autoaggressive 
behavior. More comprehensive studies on the clinical features of this patient 
were published elsewhere (Geerdink et al., 1973 and de Bruyn et al., 1973). 
As a therapy he only receives Allopurinol. Serum uric acid levels can be 
kept within normal ranges. HGPRT-activity was not detectable in erythro­
cytes, neither in the Cartier-modification nor in the more sensitive Harris-
modification (see table V I I I ) . 
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2 3 SUMMARY 
From the prcteding case reports it ran be concluded that at least two 
clinical variants of H G P R Г-dcficiencv can be distinguished The typical 
symptomatology of the Lesch-Nvhan Syndrome is coupled with a low but 
detectable H G P R Г-activity Howexer, two patients with a definitely dif­
ferent clinical picture show no detectable HGPRF-activity 
We should like to advise a perfoimante of an assay of HGPRT-activity 
in each patient with hyperuricemia even if there is no indication for the 
existence of the Lesch-Nyhan Syndrome on the basis of clinical observation 
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CHAPTER 3 
B I O C H E M I C A L F E A T U R E S O F T H E O W N P A T I E N T S 
3.1. MATERIAL AND METHODS 
3.1.1. The assay of purine nucleotides in erythrocytes 
The purine nucleotide analyses were performed according to a modifica­
tion of the method of Hurlebert et al. (1954). The erythrocytes of 20 ml 
blood were hemolyzed immediately with one volume of distilled water. To 
the obtained hemolysate 20 ml of an ice-cooled trichloroacetic acid (TCA) 
solution (10%) were added immediately. This mixture was stirred vigor­
ously and then centrifuged for 10 min at 900 χ g. T h e obtained supernatant 
was kept in an ice-vvaier bath. T h e precipitate was extracted twice with 
20 ml of an ice-cooled T C A solution (5%) and centrifuged as given before. 
The combined supernatants were extracted six times with equal volumes of 
dicthylether to remove the TCA. The resulting aqueous solution with a pH 
of about 6 was applied to a Dowex 1-X2 (200-400 mesh) column (25 χ 
0.7 cm) equilibrated with 0.8 M ammonium formate in 6 N formic acid. 
Elution was performed with two consecutive linear gradients: 
I. distilled water to 4 N formic acid (total volume 800 ml) and 
I I . 4 N formic acid to 0.8 M ammonium formate in 4 N formic acid 
(total volume 800 ml). 
Fractions of 5 ml were collected. The absorbance of the eluate was con­
tinuously registered at 254 nm. 
T h e obtained peaks were identified by pooling the fractions and measuring 
the absorbance at 260, 265. 270, 275 and 280 nm, and furthermore by paper 
chromatography of an aliquot and comparison with the authentic com­
pounds. In the case of di- and triphosphates the content of labile phosphate 
of the solutions was determined according to the method of Fiske and Sub-
barow (1925). 
T h e concentration of the identified compounds was calculated from the 
absorbance of the concerning solutions at 265 nm against a blank obtained 
by mixing equal volumes of the fraction preceding and following the peak. 
Recovery experiments were performed by addition of G M P and 8-1 ' C -
A T P to the crythroevtes before hemolysis. The recovery ranged from 95 
to 102%. 
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In every blood sample, the hemoglobin content, the hematocrit value and 
the erythrocyte count were determined according to the current laboratory 
methods. The purine nucleotide contents were expressed according to the 
formula of Hjelm (1969) as μπιοΐ/ΐ free cell water: 
μιηοΐ/ΐ packed cells 
100 χ 
1 0 0 - M C H G (g%) 
( M C H C = Mean Corpuscular Hemoglobin Concentration). 
3.1.2. The assay of purine synthesis dc novo in fibroblasts 
This assay is based on the method of Rosenbloom et al. (1968 a and b) . 
The incorporation of 1 4 C-formate or 1 4C-glycine into oc-N-formyl-glycin-
amide-ribonucleotide (FGAR) is measured. T h e conversion of FGAR to 
ct-N-formyl-glycinamidine-ribonucleotide ( F G A M ) , a reaction requiring 
glutamine which is deaminated to glutamic acid, is inhibited by the gluta-
mine antagonist azaserine (0.3 m M ) . The conversion of 5-phospho-ot-D-
ribosylpyrophosphate (PRPP) to ß-D-ribosylamine-5-phosphate, a reaction 
also requiring glutamine is not affected by azaserine at this concentration 
(Henderson and Khoo, 1965). The accumulation of 1 4C-FGAR can be 
taken as a measure for the rate of the purine synthesis de novo and especially 
for the conversion of PRPP to ß-D-ribosylamine-5-phosphate, catalyzed by 
the enzyme phosphoribosylpyrophosphate amidotransferase, the rate-limiting 
step in the purine synthesis de novo (see 1.2.2.2. ). 
The assay was performed in fibroblasts cultured from punch skin biopsies 
in Eagle's minimal essential medium to which nonessential amino acids. 
fetal calf scrum, glutamine, embryonic extract, streptomycine and penicil-
line were added. Cells were harvested by trypsinization and resuspended in 
Krebs-Ringer-Phosphate (KRP) buffer (pH 7.4). Assays were performed 
in fresh cells immediately after harvesting. 
A certain amount of cells was preincubated for 15 min at 370C in the 
presence of 8.25 mM glucose, 6 mM glycine and 0.45 m M azaserine in a 
volume of 1.0 ml K R P buffer. Then L-glutaminc and sodium 14C-formate 
(spec. act. 59 mCi/mmol, Radiochemical Centre Amersham) were added 
to final concentrations of 20 mM and 1.52 mM, respectively. The total 
volume was 1.5 ml. After an incubation period of 90 min at 370C the cells 
were washed twice with K R P buffer or sodium chloride solution (0.9%) 
and FGAR was extracted with 0.25 ml of ethanol (80%) for 30 min at 
370C. After centrifugation for 5 min at 2,500 χ g, 0.10 ml of this extract 
was spotted on Whatman 3 M M paper strips (40 χ 3 cm) and developed in 
a descending system of ethanol: water: 6N ammonium acetate (70: 25: 5; 
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by vol.). T h e dried paper strips were scanned in a Nuclear-Chicago strip-
counter and the radioactivity of the detec ted peaks was measured in a 
Nuclear-Chicago Liquid Scintillation counter. As a reference FGAR from 
different sources was used (Dr. J. F. Henderson. Edmonton Canada, Dr. 
R. W. Broekman, Birmingsham U.S.A. and Dr. J. M. Buchanan. Cambridge 
U.S.A.). The rate of purine synthesis de novo was expressed as dpm FGAR/ 
mg cells/h. 
3.1.3. The assay of HGPRT and APRT in erythrocytes 
These cn/yme assays were performed by dc Bruyn (Department of An-
thropogenetics of the University of Nijmegen) using a modification of the 
method of Harris and Cook ( 1969). For diagnostic purposes we used a modi­
fication of the method of Cartier and Hamet (1968). A certain amount of 
packed erythrocytes (about 45 mg) was hemoly/ed with 0.5 ml of distilled 
water. For HGPRT-assay with guanine as substrate this hcmolysate was 
diluted 15 times with distilled water. Incubation was performed in the 
following mixtures: 
APRT assay 
50 μΐ hcmolysate 
10 μΐ distilled water 
50 μΐ 8- 1 4C-adenine (2.4 m M ; spec, act.: 0.42 mCi/mmol) 
50 μ! Tris-HCl buffer (220 m M ; pH 7.4) 
20 μΐ MgCl 2 (50 m M ) 
20 μΐ PRPP" M g 2 salt (10 m M ) 
HGPRT assay with hypoxanthine as subiti ate 
20 μΐ hcmolysate 
40 μΐ distilled water 
50 μΐ 8- l 4C-hypoxanthine (2.4 m M ; spec, act.: 0.42 mCi/mmol) 
Tris-HCl buffer, MgCl.2 and P R P P as for A P R T assay. 
HGPRT assay with guanine as substrate 
60 μΐ diluted hcmolysate 
50 μΐ 8- , 4C-guanine (0.60 m M ; spec, act.: 1.68 mCi/mmol) 
Tris-HCl buffer, M g C l 2 and P R P P as for A P R T assay. 
Incubation was performed at 37CC for 30 min when guanine was the 
substrate and for 40 min when either hypoxanthine or adenine were the 
substrates. T h e reactions were stopped by adding 50 μΐ EDTA solution 
(80 m M ) to the mixtures in order to complex Mg + + ions which arc neces­
sary for enzymic action. A blank was realized by adding the EDTA solution 
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before the hemol)sate. An aliquot (10 μΐ) of the incubation mixture was 
spotted on Whatman 3 M M paper. Separation of radioactive compounds 
and measurement cf radioactivity were performed as described later on for 
the A M P deaminase assay (see З.1.5.). 
Radioactivity was found only in the purine bases and the corresponding 
nucleotides with a total recovery of about 100%. En/ymic activities were 
expressed as nmol/ml crythroc\tes/min and calculated from the formulas: 
APRT-activity: 
dpm AMP 30.10» 
X 
total dpm E 
HGPRT-activity with guanine as substrate: 
d p m G M P 125.103 
X 
total dpm E 
and HGPRT-activity with hypoxanthine as substrate: 
dpm I M P 75.103 
X 
total dpm E 
(E = amount of erythrocytes (mg) before hemolysis). 
3.1.4. The assay of IMP dehydrogenase in erythrocytes 
Before assaying I M P dehydrogenase, the enzyme was partially purified 
from erythrocytes. Therefore, blood from normal donors and patients with 
HGPRT-deficiency was drawn into heparinized tubes (10 units heparine/ml 
blood) and centrifuged for 15 min at 1,200 χ g. Plasma and buffycoat were 
removed. The erythrocytes were resuspended in at least five \olumeb of a 
cold sodium chloride solution (Ό.9%), centrifuged for 10 min at 1,200 χ g 
and the supernatant and residual buffycoat were removed again. This 
washing procedure was repealed once. The washed packed erythrocytes were 
frozen at -20 o C and thawed again to hemolyze the cells. The hemolysate was 
dialyzed overnight against 0.01 M Tris-HCl buffer (pH 8.0). The dialyzcd 
hemolysate was treated with DEAE-sephadex A 50 (2.5 g/10 ml of hemoly­
sate) and the obtained mixture was stirred during 30 min at 0 C C and then 
centrifuged for 15 min at 1.200 χ g. T h e supernatant was discarded and the 
remaining DEAE-sephadex was stirred for 30 min at 0 o C with 0.066 M 
Tris-HCl buffer (pH 8.0) containing 0.03 M potassium chloride. The ob-
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tained suspension was centrifuged for 15 min at 1,200 χ g and the super­
natant was discarded. This washing procedure was repeated until the red 
color of hemoglobin had disappeared (about five washings were necessary). 
T h e washed DEAE-sephadex was poured into a glass column of adequate 
measures. This column was washed with a solution of 0.3 M potassium 
chloride in 0.066 M Tris-HGl buffer (pH 8.0) until no more material ab­
sorbing at 254 nm could be removed from the column. 
T h e eluatc was concentrated by putting it into a dialyse-tubc and bedding 
this in Sephadex G 25 (coarse) to extract water and low molecular weight 
substances. After the concentrating procedure, the protein content of the 
obtained solution was estimated according to the method of Lowry et al. 
( 1951 ). Unless otherwise stated protein content was determined according to 
this procedure. 
The activity of I M P dehydrogenase was assayed according to Magasanik 
(1963) by incubating an aliquot of the concentrated en/yme solution in the 
presence of 8- 3 H-IMP (8.3 χ 10-Γ'Μ; spec. act. - 2,000 mCi/mmol), potas­
sium chloride (4.55 χ 10- 2M), reduced glutathione (4.55 χ lO-tM), NAD+ 
(9.10 χ 10- 4 M). Tris-HCl buffer, p H 8.0 (4.55 χ l O ^ M ) in a total volume 
of 220 μΐ. After incubation for 0 to 3 h at 3 7 0 C the reaction was stopped 
by addition of 20 μΐ of 5 % T C A to the incubation mixture. T h e precipitated 
protein was removed by centrifugation for 20 min at 1,200 χ g. Next 20 μΐ 
of the supernatant were spotted on Whatman DE - 81 paper with carrier 
G M P , I M P and X M P . Ascending paperchromatography in 0.2 M am­
monium formate - formic acid buffer (pH 5.0) was performed. After drying, 
the spots were detected with an ultraviolet light source. The spots were cut 
out and treated with Soluene - 100 (Packard) to solubilize the paper. After 
addition of 15 ml of liquid scintillation solvent, the radioactivity of the spots 
was measured in a Nuclear-Chicago Liquid Scintillation Counter. Only the 
spots of I M P and X M P showed detectable radioactivity. 
T h e enzymic activity was calculated according to the formula: 
dpm X M P pmol of I M P originally present in the incubation mixture 
X ; ; ; ; ; ; 
total dpm incubation time (h) χ protein content in the incubation 
mixture (mg) 
Enzymic activity was expressed as pmol/mg protein/h. The total recovery 
of radioactivity was found to be about 100%. 
3.1.5. The assay of AMP deaminase in erythrocytes 
We used a modification of the method of Setlow et al. (1966). The 
activity of the enzyme A M P deaminase was assayed in dialyzed hemolysate. 
The hemolysate was prepared by destroying washed erythrocytes with 
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distilled water and centrifuging the ghosts. The final hemoglobin concen­
tration of the obtained hernolysates was about 2 mmol/l. The hemolysate 
was dialyzed three times against 1.5 1 sodium chloride solution (0.9%) and 
three times against 1.5 1 distilled water. After centrifugation the incubation 
was performed in the following way: to 100 μΐ of a Tris-HCl buffer (pH 
7.2: 110 m M ) containing potassium chloride (300 m M ) and reduced 
glutathione (45 m M ) was added 50 μΐ AMP solution (12 rnM), 50 μΐ ATP 
solution (6 m M ) , 10 μΐ S-^C-AMP solution (50 μϋί/ιηΐ) and 50 μΐ of 
hemolysate. The specific activity of AMP was 54 mCi/mmol. After incuba­
tion for 15 min at 37 0 C the reaction was stopped by adding 100 μΐ T C A 
solution (20%) or heating the incubation mixture at 100oC for 2 min. 
A blank was realized by addition of the TCA solution before the hemolysate 
or boiling the latter before. After stopping the reaction the test tubes were 
centrifuged at 2.500 χ g. Thereafter 20 μΐ of the supernatant were spotted 
on Whatman 3 M M paper. Radioactive compounds were separated by 
high voltage electrophoresis (Carnag) in pyridine: glacial acetic acid: water 
(10 : 100 : 890; by vol.: pH 3.6), at 60 V/cm during 45 min. The paperstrips 
were scanned in a Nuclear-Chicago stripcounter, the radioactive peaks were 
cut out and radioactivity was measured in a Nuclear-Chicago Liquid Scin­
tillation Counter. The enz)rnic activity was calculated from the formula: 
dpm I M P μιηοΐ of A M P originally present in the incubation mixture 
χ '. 
total dpm incubation time (h) χ hemoglobin in the incubation 
mixture (g) 
Enzymic activity was expressed as μηποί^ hemoglobin/h. The recovery of 
total radioactivity was found to be 100%. 
3.1.6. The assay of adenosine deaminase in erythrocytes 
This assay was performed with hemolysate whether or not dialyzed. The 
hemolysate was obtained as described for AMP deaminase assay (see 3.1.5.). 
A 10 μΐ of hemolysate or dialyzed hemolysate was incubated with 90 μΐ of an 
isotonic phosphate buffer solution (pH 7.4) and 20 μΐ adenosine-8-1 4C 
solution (0.7 m M ; spec, act.: 6 mCi/mmol). After incubation for 5 to 10 min 
at 37 0 C the reaction was stopped by adding 50 μΐ EDTA solution (0.1 m M ) 
to the incubation mixture in order to complex M g + + ions. A blank was 
realized by adding the EDTA solution before the enzyme solution. After 
centrifugation of the test tubes at 2,500 χ g, 20 μΐ of the supernatant were 
spotted on Whatman 3 M M paper. High voltage electrophoresis and meas­
urement of radioactivity were performed as described for A M P deaminase 
(see 3.1.5.). Adenosine and inosine were the only radioactive compounds 
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that could be detected. T h e enzymic activity was calculated from the for­
mula: 
μπιοί of adenosine originally present in the incubation 
dpm inosine mixture 
X ; ; ; ; ; ; — 
total dpm incubation time (h) X hemoglobin in the incubation 
mixture (g) 
Enzymic activity was expressed as μπιοΐ/g hemoglohin/h. The total recovery 
of radioactivity was found to be 100%. 
3.1.7 Measurement of radioactivity 
All countings were performed in a Nuclear - Chicago Liquid Scintillation 
Counter (Mark I) by addition of 15 ml of scintillation solvent to the sample. 
T h e scintillation solvent was composed of: 
1,000 ml toluene 
1,000 ml cthylenglycolmonomethylether 
8 g 2,5-diphenyloxazol (PPO) 
200 mg 2.2'-p-phenylen-bis-(4-methyI-5-phenyloxazol) (Dimcthyl-POPOP). 
3.1.8. The away of purine synthesif de novo in vivo 
We used the same method as performed by Benedict et al. ( 1952). Lesch 
and Nyhan (1964) and van der Zee et al. ( 1970). Van der Zee (1972) gave 
a very detailed description of the performance of the assay. The principle 
of the method has been given in 1.2.2. 
3.2. RESULTS 
3.2.1. Purine nucleotides in erythrocytes 
I n t r o d u c t i o n : 
The purine nucleotides play a very important role in the purine metabo­
lism. They can be synthetized de novo but additional routes for their forma­
tion are known; among other things by means of the H G P R T and A P R T 
catalyzed conversions of purine bases into purine nucleotides. Purine nucleo­
tides exhibit a feed-back inhibition on the rate-limiting step of the synthesis 
de novo. 
The enzyme H G P R T is of utmost importance in the resynthesis of I M P 
and G M P from hypoxanthine and guanine, respectively. So. it seemed 
worthwhile to determine the concentrations of purine nucleotides in erythro-
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cytes of patients with HGPRT-deficiency as aberrations could be expected. 
Purposeful erythrocytes have been chosen since the purine synthesis de novo 
is interrupted in these cells (Lowy and Williams, 1960; Lowy et al., 1961 
and 1962, Fontenclle and Henderson. 1969) by which an expected decrease 
in the concentrations of I M P and G M P could not be influenced by an 
increased purine synthesis de novo. 
R e s u l t s : 
The purine nucleotide concentration determined in erythrocytes of children 
of varying ages without metabolic, hematological, neurological or mental 
disease and of 5 patients with HGPRT-deficiency, appears from table VI. 
Three of these patients, the two brothers A 1 and A.., and the unrelated В 
suffer from the Lesch-Nyhan Syndrome in the classic form with hyper­
uricemia, mental deficiency, ataxia, cerebral palsy, selfdestructive behavior 
and megaloblastic anemia (as described in Chapter 1 and 2). In these 
patients purine nucleotides had been determined before and during oral 
administration of adenine. Furthermore, the purine nucleotides had been 
determined in erythrocytes of patient C 1 (5 years) and his uncle C·, (35 
years) with HGPRT-deficiency, hyperuricemia, developmental retardation 
and slight neurological disorders, but without selfdestructive behavior or 
ataxia (see Chapter 2). 
From table VI it can be seen that the concentrations of the various purine 
nucleotides in erythrocytes of the controls vary in a small range. The values 
for the controls agree with those reported by Albaum et al. (1951), Bishop 
et al. (1959), Hjelm (1969) and Mills et al. (1971). T h e nucleotides that 
were always found in detectable amounts in erythrocytes of controls were 
AMP. ADP, A T P and G T P . Traces (about 1 μιηοΐ/ΐ free cell water) of 
I M P and G D P were found sometimes in the controls. Neither IDP, I T P nor 
G M P were ever detectable. 
In the patients A], Ao and В before the adenine administration, the con­
centration of AMP, ATP and especially ADP were decreased obviously in 
comparison with the controls. The G T P concentration was within the normal 
range. I M P , IDP. I T P , G M P and G D P were not found. 
In patient C, and his nephew C, the decrease of the three adenine 
nucleotides was much more expressed and the G T P concentration was in­
creased obviously. In contrast to the controls and the three other patients 
G M P , G D P and I M P were found in erythrocytes of those two patients in 
remarkable amounts. 
After oral treatment of the patients A,, A.> and В with adenine (heir 
adenine nucleotide concentrations in erythrocytes became within normal 
ranges. The G T P concentration was found to be normal or only slightly 
increased. 
T h e differences between the three nucleotide patterns appear from fig. 6. 
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Table VI 
PURINE NUCLEOTIDES IN E R Y ! H R O C Y l E S OF PATIENTS W i l l i HGPRT-DEFICIENCY 
(μπιοΐ/ΐ of free cell water) 
I 
I I 
I I I 
Patients 
Before adenine treatment 
Αι 
M 
В 
Ci 
Ci 
During adenine treatment 
Ai 
As 
В 
Normal (Ν - 12) 
(Mean ± 1 s d ) 
AMP 
32 2 
35 7 
34 5 
30 0 
31 0 
41 5 
40 0 
41.2 
37 9 ± 2 03 
ADP 
118 
111 
124 
90 
96 
229 
228 
225 
224 i- 30 
Λ Ί Ρ 
1500 
1580 
1670 
1187 
1210 
1980 
1960 
1957 
1830 ± 110 
I M P 
ν 
--
--
9 
8 
— 
— 
G M P 
— 
— 
— 
20 
17 
--
— 
— 
-
G D P 
-
— 
— 
90 
81 
— 
-
-
-
G T P 
n: 
120 
108 
170 
155 
127 
126 
126 
103 ± 10 
*: not detectable (below 1 μηιοΐ/ΐ of free cell water) 
D i s c u s s i o n : 
Several investigators searched for the cause of the increased purine syn­
thesis de novo in HGPRT-deficiency. Rosenbloom et al., (1968 a and b) 
discussed the following suppositions: 
090 J 
080 
.1 - normal 
-pat. В 
• pal. Ci 
0.75 -) 
0.70-
0.10 
0.05 -
u 
AMP 
100 
GMP IMP ADP 
200 
GDP-ATP-GTP 
300 fraction nr. 
Fis- 6. Purine nucleotide pattern of erythrocytes from patients and controls. 
1. T h e decreased resynthesis of G M P and I M P results in a higher availa­
bility of 5-phospho-a-D-ribosyl-pyrophosphate (PRPP) for the synthesis of 
ß-D-ribosylamine-S-phosphate (fig. 1.). 
2. In HGPRT-deficient fibroblasts, PRPP amidotransferase is activated 
by hypoxanthine and guanine which are found to be inhibitors in normal 
cells via their corresponding nucleotides (see 1.2.1.). 
3. A decreased feed-back inhibition of purine synthesis de novo caused 
by a decreased concentration of purine nucleotides. Rosenbloom examined 
the purine nucleotide concentration of normal fibroblasts and that of 
HGPRT-deficient patients, and found no significant difference between 
both kinds of cells. However, these fibroblasts were cultured in a medium 
containing a large amount of glutamine which is a precursor in purine syn-
thesis de novo. Ghadimi et al. (1970) concluded from the study of Seeg-
miller et al. (1967) that HGPRT-deficient cells contain an increased 
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amount of ΛΜΡ However, this conclusion is based on an erroneous inter­
prétation of the results of Seeçmiller and co-workers, who only demonstrated 
that ЛРКГ-асП\Н> is higher in HGPRT-deficient ervthroevtes than in 
normal ones Manzke (1967) and Labrum* et al (1%9) determined the 
concentrations of AMP, ADP and ΛI Ρ per liter of erv throe ) tes in patients 
with the Lesch-Nvhan Syndrome Man/ke found normal values but calls 
his method in question himself Labrune and co-workers found increased 
values for adenine nucleotides but the authors did not mention their methods 
of determination Furthermore, these determinations were performed a few 
days after a bloodtransfusion So, the validity of their results is doubtful 
I he present investigations demonstrate that erythrocytes from patients 
with H G P R I -deficiency possess a decreased concentration of adenine nu­
cleotides, whereas the coruentration of guanine nudeotides is normal or 
even increased One group of patients \
u
 \ j and В were treated orally with 
adenine After treatment adenine nucleotides have been normalued and the 
G l Ρ concentration shows a slight increase 
Van der Zee et al (1970) demonstrated that the in VILO purine synthesis 
de novo in H G P R Г-deficient patients decreased after adenine ticatment 
This finding is in accordance with the normalization of adenine nucleotides 
since the decrease of purine synthesis de novo could be caused bv an increase 
of feed-ba< к inhibition by adenine nucleotides 
T h e results described in this chapter focus our attention to the role of 
adenine nucleotides in the legulation of the purine synthesis de novo 
Comparison of the nucleotide patterns of the patients with those of the 
controls justifies the supposition that in both groups of patients (with and 
without the typical features of Lesth-Nvhan Svndromc) there is a shift of 
the adenine nucleotides towards the guanine nucleotides as described pre-
MOUSK (Lommen et a l , 1971) In the patients C, and C_>, however, this 
shift is much more expressed than in the three other patients The concen­
tration of adenine nucleotides is stronger decreased, the G l Ρ concentration 
is increased and furthermore, the nucleotides G M P , G D P and I M P are e\en 
present m measurable amounts These nucleotides were never found before. 
neither in HGPRT-deficient erythrocytes nor in normal ones 
Before discussing the mechanisms which could be responsible for the shift 
mentioned afore, a general consideration concerning the concentrations of 
purine nucleotides in a < ell will be given 
Ί he intracellular concentration of purine nucleotides is the resultant of 
synthesis, break-down and transport of the nucleotides birst of all we shall 
discuss those mechanisms in a cell in general 
Purine nucleotides are synthelized either in the purine synthesis de noto 
or res) nthctized from purine bases (see 12 1 ) The synthesis de novo results 
in the formation of I M P which can be converted either via X M P into G M P 
or lia S - \ M P into \ M P I h e monophosphonucleotides can be converted 
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into di- and triphosphonucleotidcs. The purine bases are derived intrarellu-
larly from the break-down of nucleic acids or extracellularly via transport 
by the body fluids. 
The catabolism of the nucleotides can be seen from fig. 4. This catabolism 
results in the endproduct uric acid which leaves the cell and is transported 
by blood towards the kidney and the intestinal system to be removed from 
the body. The purine bases which occur as metabolites in this catabolism 
can be reutilized in the afore mentioned resynthesis of purine nucleotides 
if necessary. 
Oci and dc Bruyn (1973) postulated that the intracellular purine nucleo-
tide concentration also depends on another factor. Their in vitro experiments 
showed that in the presence of red cell membranes G M P and I M P are able 
to enter the intact erythrocyte, lymphocyte and cultured skin fibroblast. Till 
now it is not clear whether there is either an entrance of nucleotides as such 
or the nucleotides are metabolized before and are resynthetized intracellu-
larly. The fact that this incorporation of nucleotides took place in H G P R T -
deficient cells too, excludes a role of this enzyme in this incorporation. 
The mutual relationship between the various purine nucleotides is influ-
enced by the activities of the enzymes involved in the interconversion of the 
monophosphoribonucleotides (fig. 5.). 
All mechanisms mentioned afore concern onh a metabolically complete 
cell. Whereas the erythrocyte is an incomplete cell, the situation is different 
in some ways. First of all the purine synthesis dc novo in the mature erythro-
cyte is interrupted since the erythrocyte lacks several enzymes involved in this 
synthesis de novo (Lowy and Williams, 1960; Lowy et al., 1962; Fontenelle 
and Henderson, 1969). Furthermore, the mature human erythrocyte lacks 
the enzyme adenylosuccinate lyase (Lowy et al., 1961 and 1962; Fontenelle 
and Henderson, 1969). So. the conversion of I M P into AMP is impossible 
in the erythrocyte. 
The nucleotides of the mature erythrocytes have been synthetized partly 
during the maturation period in the bone marrow. 
It is obvious that the purine metabolism is quite different in H G P R T -
deficient cells as no resynthesis of the purine nucleotides GMP, IMP and 
X M P takes place. 
Considering the afore mentioned results with respect to the analysis of 
purine nucleotides several mechanisms can be mentioned which could be 
responsible for those results. 
1. Balis (1968) and Sorenscn (1970) postulated that H G P R T completes 
the sequence of reactions in an interconversion of AMP via adenosine, 
inosine and hypoxanthine into IMP. The deficiency of this enzyme results 
in a depletion of adenine nucleotides, by leakage via adenosine, inosine, 
hypoxanthine, xanthine and uric acid (fig. 4.) . 
2. In pursuance of the findings of Pehlke et al. (1972) we established a 
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remarkable difference in the properties of the enzyme I M P dehydrogenase 
(partially purified from erythrocytes) from normal erythrocytes and 
bIGPRT-deficient ones (see 3.2.4.). I M P dehydrogenase from normal ery­
throcytes is strongly inhibited by 2,3 diphosphoglyceric acid, a substance 
which is present in erythrocytes (normal and HGPRT-deficient ones) in 
large amounts (about 5 mmol/1 free cell water). The enzyme obtained from 
HGPRT-deficient erythrocytes, however, is completely insensitive to this 
inhibition (Lommen et al., 1973). T h e afore mentioned difference can be 
one of the factors which cause the decrease of the adenine nucleotides on 
the one hand and it can be helpful in the maintenance or increase of the 
concentration of the guanine nucleotides on the other hand. 
3. Another mechanism responsible for the unexpected normal or increased 
concentrations of I M P and guanine nucleotides is based on the increased 
purine synthesis de novo in HGPRT-deficient individuals. The normal or 
even increased amounts of guanine nucleotides and I M P in HGPRT-defi­
cient erythrocytes in spite of the interruption of the synthesis de novo can be 
explained on the basis of the following hypotheses: 
a. during the maturation period of the erythrocyte the enhanced synthesis 
de novo results in a normal or increased concentration of I M P and 
guanine nucleotides which can be maintained during circulation of the 
mature erythrocyte. 
b. the nucleotides produced in other tissue cells enter the erythrocyte by the 
mechanism postulated by Oei and de Bruyn (1973). 
с the concentration of 5-aminoimidazole-4-carboxamide (AIC) and of its 
nucleotide in serum and urine of HGPRT-deficient individuals is in­
creased (Ncwcombe et al., 1967; Newcombe. 1970; Sweetman, 1970). 
AIC might be converted into 5-aminoimidazole-4-carboxamide-ribonu-
cleotide (AICAR) by the enzyme A P R T in erythrocytes following entry 
into the cell (Lowy and Williams, 1960; Lowy et al., 1962; Fontenellc 
and Henderson, 1969; Krenitsky et al., 1969a). Mature erythrocytes can 
convert AIC AR into I M P (see fig. 1.). So, the increase of the serum 
AIC concentration could result in extra I M P production in mature 
HGPRT-deficient erythrocytes. 
The afore mentioned shift increases with a decrease of the remaining 
HGPRT-activity as can be concluded from the finding of the increased 
concentration of I M P , G M P , G D P and G T P in the patients C, and C2 
in which no HGPRT-activity was detectable and the normal concentration 
of G T P and absence of the other nucleotides in the patients A), A2 and В 
in which a remaining activity of H G P R T of 0.5 - 1% of normal activity 
was found (see З.2.З.1.). 
Possibly we deal with two variants of HGPRT-deficiency with different 
clinical and biochemical features, one with the typical symptomatology of 
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the Lesch-Nyhan Syndrome and one with more mild symptomatology with-
out sei f destructive behavior. 
3.2.2. Purine synthesis de novo in fibroblasts 
I n t r o d u c t i o n : 
The discovery of 2 patients with HGPRT-deficiency and a clinical picture 
quite different from the Lesch-Nyhan Syndrome called up the question 
whether the purine synthesis de novo was increased to the same extent in 
these patients as compared to typical Lesch-Nyhan patients. For that reason 
the purine synthesis de novo was measured in fibroblasts of one of the 
patients ( G , ) . by measuring the incorporation of 14C-formate into FGAR. 
Furthermore, the influence of some purine bases on the synthesis de novo 
was investigated. The obtained data were compared with those from normal 
fibroblasts. 
R e s u l t s : 
Table V I I shows that the purine synthesis de novo in fibroblasts from 
patient C, is increased excessively in comparison with that in normal fibro-
blasts. Furthermore, it has been demonstrated that the purine synthesis in 
the IIGPRT-deficient fibroblasts is not inhibited but seems to be even 
activated by hypoxanthine in contrast to a definite inhibition in normal fibro-
blasts. However, addition of adenine to the incubation mixture resulted in 
an inhibition of the purine synthesis de novo in both kinds of cells. 
Table VII 
INFLUENCE OF PURINE BASES ON PURINE SYNTHESIS DE NOVO 
IN FIBROBLASTS OF A HGPRT-DEFIGIENT INDIVIDUAL 
AND OF A NORMAL ONE 
Addition 
hypoxanthine 
adenine 
hypoxanthine 
guanine 
Patient Ci 
dpm FGAR/mg cells/h 
4,050 
2,580 
4.950 
— • 
% 
100 
64 
122 
—-
Control 
dpm FGAR/mg cells/h 
690 
415 
595 
570 
% 
100 
62 
86 
83 
Purine synthesis de novo was measured by incorporation of 14C-formate into FGAR 
in the presence of azaserine 
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D i s c u s s i o n : 
These results are in accordance with the findings of Rosenbloom et al. 
(1968 a and b) in fibroblasts of patients with the Lesch-Nyhan Syndrome. 
The purine synthesis de novo in the HGPRT-deficient fibroblasts amounts 
to 6 times that of normal fibroblasts. Furthermore, in the HGPRT-deficient 
cells the purine synthesis is not inhibited by hypoxanthine (Rosenbloom et 
al.. 1968 a and b) . In accordance with Rosenbloom et al. (1968 a and b) 
we found the FGAR accumulation in HGPRT-deficient cells in the presence 
of hypoxanthine increased. The failure of hypoxanthine to inhibit the purine 
synthesis de novo is due to the inability of HGPRT-deficient fibroblasts to 
convert hypoxanthine into IMP. 
The inhibiting effect of adenine on the purine synthesis de ?iovo was 
equal in both HGPRT-posilive fibroblasts and HGPRT-negative ones. 
From these findings it may be concluded that patient C, has an accel­
erated purine synthesis and that the hyperuricemia in this patient is of the 
overproduction type like in the patients with the Lesch-N\han Syndrome. 
Further support for this supposition will be yielded by the findings on the 
purine synthesis de novo in vivo (see 3.2.7.). 
3.2.3. HGPRT and APRT in erythrocytes 
3.2.3.1. H G P R T 
Two different methods for assaying this enzyme were used (sec З.1.З.). 
For diagnostic purposes we used the method of Cartier and Hamet (19681. 
In this rather insensitive method none of the 5 patients showed any H G P R T -
activity in the erythrocytes, distinguishable from the blanks. However, the 
method of Harris and Cook (1969) as modified by de Bruyn revealed a dis­
tinct remaining HGPRT-activity in the erythrocytes of the patients A), Ao 
and B. No activity could be established in the patients С, and Co ( table V I I I ). 
T h e detection limit of this method amounts to 0.5 nmol/mg protein/h with 
hypoxanthine as svibstrate. 
From these results it may be concluded that the symptomatology of 
HGPRT-deficiency is not directly related to the degree of the deficiency. 
The 3 patients with the severe and fully developed clinical features of the 
Lesch-Nyhan Syndrome show a low but definitely detectable activity whereas 
in the two patients with a mild neurological disturbance and no signs of 
selfdestructive behavior not any enzymic activity could be detected. 
Investigations of lymphocytes of the various patients according to the 
Harris-modification yielded an identical pattern as found for erythrocytes: 
a low but detectable HGPRT-activity was present in lymphocytes obtained 
from the patients Aj, A.j and В and no activity was found in the lymphocytes 
obtained from the patients C^ and Co. 
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Table V i l i 
T H E ACTIVITY OF H G P R T AND APRT IN HEMOLYZED ERYTHROCYTES OF PATIENTS AND CONTROLS 
Eru>mc 
Assay method 
Substrate 
At 
A2 
В 
Ci 
C-2 
Normal (N = 12) 
(Mean ± 1 s.d.) 
H G P R T 
Cartier modifie, m 
nrnol/ml 
Hypoxanthine 
not detect 
not detect. 
not detect. 
not detect 
not detect 
323 ± 91 
er> /min 
Guanine 
not detect. 
not detect. 
not detect. 
not detect 
not detect. 
710 ± 121 
Harris mo 
nmol/mg 
Hypoxanthine 
; 0.5 
-: 0.5 
5 
not detect. 
not detect. 
77 ± 17 
idific. in 
prot/h 
Guanine 
. -
--
-
. 
APRT 
Cartier modifie, m Harris modifie, in 
nmol/ml ery/min nmol/mg prot/h 
Adenine 
180 
241 
212 
134 42 
Adenine 
140 
100 
65 
28 
51 3 
23 ± 7 
3.2.3.2. A P R T 
T h e APRT-activity was definitely higher in the erythrocytes of all patients 
except of patient Cj as compared to controls, tested both according to the 
Cartier-modification and to the Harris-modification (see table V I I I ) . These 
findings agree with those of other authors (Seegmiller et al., 1967; Kelley et 
al., 1967 and 1969; Kelley, 1968; Henderson et al., 1969; Sorensen, 1970). 
Furthermore, de Bruyn confirmed in our 5 patients the findings of Hender­
son et al. (1969), Kelley et al. (1969) and Greene et al. (1970) that the 
A P R T from erythrocytes from HGPRT-deficient individuals showed an 
increased heat-stability as compared with A P R T obtained from normal 
erythrocytes. 
3.2.4. IMP dehydrogenase in erythrocytes 
I n t r o d u c t i o n : 
From the experiments described previously (sec 3.2.1.) it was concluded 
that the balance between the monophosphoribonucleotides AMP, I M P and 
G M P was disturbed as a result of a shift of adenine nucleotides via I M P , 
X M P towards the guanine nucleotides. This shift disappeared after treat­
ment of the patients Aj. AL) and В with adenine. One of the reactions in­
volved in the conversion of AMP into G M P is the irreversible oxidation of 
I M P to X M P which is catalyzed by inosinic acid dehydrogenase ( I M P dehy­
drogenase). Pehlke et al. (1972) assayed the activity of this enzyme for the 
IMP dehydrogenase act iv i ty 
in p r 
230 л 
220-
210-
200-
1 9 0 -
180 
nol 
С 
I 
¿ 
' m g p ro te in /h r 
Controls 
ì 
! „ 
ί 
ί 
ì 
• 9 
170-t A 
160-1 | , , 1 
0 100 200 300 
pa t ien ts 
ПИ 
1 A
 é 1 
0 100 200 300 
η mol 2,3 DPG added to the incubation medium 
Fig 7. The influence of 2,3 DPG on the activity of IMP dehydrogenase 
of erythroc>tes from 5 patients and 4 conti oís. 
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first time in human erythrocytes. They found a significant increased enzymic 
activity in erythrocytes of patients with HGPRT-deficiency as compared 
with normal erythrocytes. They concluded that this inrrease was due to the 
absence of an unidentified, dialysable inhibitor in erythrocytes of patients, 
which is present in normal erythrocytes. 
Because 2,3-diphosphoglyceric acid (2,3 DPG) is a well-known inhibitor 
of the enzyme adenylic acid deaminase (AMP deaminase) (Askari and Rao, 
1968), which catalyzes the conversion of A M P into I M P , our attention was 
focused on the eventual influence of 2,3 D P G on I M P dehydrogenase. In 
erythrocytes 2,3 D P G was found in very high concentrations (about 5 mmol/1 
free cell water). No difference was found between the 2,3 D P G concentra­
tions in the erythrocytes of the 5 patients and 4 normal individuals (Dr. J. 
Wessels, Dept. of Internal Medicine). 
We investigated the influence of 2,3 D P G on partially purified I M P 
dehydrogenase from normal and HGPRT-deficient erythrocytes. 
R e s u l t s : 
Fig. 7. shows the results of the I M P dehydrogenase assay in the partially 
purified protein fraction from normal erythrocytes (4 individuals) and 
HGPRT-deficient ones (5 patients) both in the presence and absence of 
2,3 DPG. The enzymes of HGPRT-deficient erythrocytes and of normal 
ones showed almost the same activity in the absence of 2.3 DPG. However, 
after addition of 2,3 D P G to the incubation mixture the activity of the 
enzyme obtained from normal erythrocytes showed a decrease proportionally 
to the concentration of 2,3 D P G whereas the activity of the enzyme obtained 
from HGPRT-deficient erythrocytes remained nearly constant. In a separate 
experiment we investigated the influence of high concentrations 2.3 D P G 
(5 pmol added to the incubation mixture of 220 μΐ). The controls" enzyme 
showed a decrease in activity of 70%, whereas in the patients Ai and A2 
no inhibition was found. No significant differences were established between 
the two groups of patients as concerning to the influence of 2,3 D P G on 
I M P dehydrogenase. 
D i s c u s s i o n : 
These findings seem to be in contradiction to the conclusion of Pehlke 
et al. (1972). They postulated that the increased I M P dehydrogenase ac­
tivity in HGPRT-deficient erythrocytes was due to the absence of an un­
identified dialysable inhibitor which is present in normal erythrocytes. 
O u r results do suggest that HGPRT-deficient erythrocytes contain I M P 
dehydrogenase with different behavior with respect to 2,3 DPG. T h e differ­
ence in activity between both kinds of enzymes is probably not due to the 
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absence of an inhibitor in HGPRT-deficient erythrocytes but is caused by 
an altered I M P dehydrogenase which is not inhibited by 2,3 DPG. 
In the afore mentioned experiments the concentration of 2,3 D P G varies 
from about 5 to 15 times that of the substrate I M P except for the separate 
experiment where 5 μιηοΐ of 2,3 D P G were added, resulting in a 2.3 D F G 
concentration of 250 times that of I M P . The 2,3 D P G / I M P ratio in cir­
culating erythrocytes in which I M P is not measurable (below 5 μιτιοί per 
1 free cell water; З.2.1.), and the concentration of 2.3 DPG amounts to 
5 mmol per 1 free cell water is much higher. So, in normal erythrocytes I M P 
dehydrogenase will be strongly inhibited. It is highly probable that the 
inhibitor proposed by Pehlke et al. (1972) is identical with 2,3 DPG. 
Either I M P dehydrogenase in erythrocytes of HGPRT-deficient indi­
viduals represents a mutant en/yme or there are other factors causing the 
afore mentioned remarkable findings. This question has to be subject of 
further and more comprehensive investigations. 
3.2.5. AMP deaminase in erythrocytes 
I n t r o d u c t i o n : 
In view of the proposed shift of adenine nucleotides towards guanine 
nucleotides the first reaction in this shift, namely the A M P deaminase cata­
lyzed conversion of A M P into I M P was studied. This reaction is extremely 
sensitive to inhibition by 2,3 DPG (Askari and Rao, 1968). 
R e s u l t s : 
Table I X shows the results of the assay of A M P deaminase in 3 patients 
Table IX 
THE ACTIVITY OF ΛΜΡ DEAMINASE IN IIEMOLYZED ERYTHROCY'I ES 
OF PAI IENTS AND CONTROLS 
Enzymic activity 
^mol/g hemoglobin/h) 
1086 
332 
655 
280 
420 ± 70 
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Patient before therapy 
Ci 
Patients during therapy 
Ai 
Aa 
Ci 
Controls (Ν = 7) 
Mean ± 1 s.d. 
as compared to the activity in 7 normal individuals. Λ11 3 patients were 
invebtigated during therapy. Patient A] and Лч received adenine and Allo­
purinol and patient C, received Allopurinol only. Furthermore, we inves­
tigated patient C] before he received therapy. It appears that the patients 
Aj and C! with therapy show an enz^mic activity within normal ranges. 
However, patient A^ shows a significant increase of enzymic activity. Fur­
thermore, before receiving therapy patient Cj shows an activity which is 
2 to 3 times the normal activity. 
Table X 
T H E ACTIVITY OF ADENOSINE DEAMINASE IN HEMOLYZED 
ERYTHROCYTES AND C O N T R O L S 
Patients Enzymic activity 
(pmol/g hemoglobin/h) 
A! 480 
A2 348 
С ι 284 
Normal (N = 6) 
Mean ± 1 sd . 380 ± 83 
D i s c u s s i o n : 
The finding of an increased A M P deaminase activity in erythrocytes of 
the patients A^ and C, fits very well to an increased conversion of adenine 
nucleotides via I M P towards guanine nucleotides (see З.2.1.), especially if 
this finding is combined with the results of the I M P dehydrogenase activity 
in the patients' erythrocytes. However, this observation has to be taken 
very carefully because it is only a finding in two patients. Furthermore, the 
mechanism which is responsible for the normalization of A M P deaminase 
activity in patient С
 i during Allopurinol therapy is not elucidated yet. 
3.2.6. Adenoúne deaminase in erythrocytes 
I n t r o d u c t i o n : 
In view of the hypotheses of Balis (1968) and Sorensen (1970) who pos-
tulated a depletion of the adenine nucleotides in HGPRT-deficient cells (see 
3.2.1.) by leakage via adenosine, hypoxanthine, xanthine to uric acid it 
seemed to be worthwhile to investigate one of the most active enzymes in this 
pathway: adenosine deaminase. The enzyme catalyzes the conversion of 
adenosine into inosine. 
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R e s u l t s : 
Comprehensive experiments revealed that there was no significant differ­
ence in eriz>mic activity between crude hemolysates and dialyzed ones. 
From table X it appears that there is no difference between the activity of 
this enzyme obtained from erythrocytes from normal individuals and those 
from both groups of patients with HGPRT-deficiency. 
D i s c u s s i o n : 
The decrease of adenine nucleotides in erythrocytes from patients with 
HGPRT-deficiency is not due to an increase of the activity of adenosine 
deaminase. However, it is not excluded that an alteration in one of the other 
enzymes involved in the pathway as postulated by Balis and Sorensen. may 
cause an increased drain of adenine nucleotides. 
3.2.7. The in vivo incorporation of l4C-glycinc into urinary uric acid 
Van der Zee (1972) reported already the results of these investigations 
in the patients Αι and Λ2 (van der Zee's patients II;¡ and II5) . In this 
cumulative % orally MC 
excreted as uric acid 
25-1 
pat Ci 
Fig 8 Ί he cumulative excretion of ' 'C in urinarv uric acid by patient Ci during 
7 da>s after administration of 2-"C-glvcine Control values originate 
from Lesch and Nyhan (1904). 
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thesis the patient C j has been investigated as to the purine synthesis de novo 
in vivo before he received any therapy. 
The total incorporation of * 'C-glycine into urinary uric acid after 7 days 
was 2.23% of the administered dose. Fig. 8. represents a graphic expression 
of the cumulative percentage of orally given ^ C excreted as urinary uric 
acid in patient C j . This curve is identical to those which were given by van 
der Zee (1972) for the patients A l and Aa before treatment. So, it can be 
concluded that there is no significant difference in the increase of the in vivo 
purine synthesis de novo in the patients with the Lcsch-Nyhan sympto-
matology and one of the patients with the more mild symptomatology. 
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CHAPTER 4 
GENERAL DISCUSSION AND C O N C L U S I O N 
The most remarkable finding of the present investigation consists of the 
establishment that patients with HGPRT-deficiency can not be delected 
always on the babis of the clinical features. This statement is supported by 
our study of two groups of patients suffering from diseases which can be 
distinguished clinically in many symptoms but exhibit biochemically similar 
abnormalities. This observation is of utmost importance for those physicians 
and biochemists being occupied with the investigation of patients suffering 
from an inborn error of metabolism . 
Our findings stimulated us to perform a study of patients with HGPRT-
deficiency described in the literature. It has been pointed out in Chapter 1 
that several patients with this enzyme deficiency showed clinical pictures 
which differed in symptomatology. Early developmental retardation, hypo-
tonia and later on spasticity especially from the legs were the only symptoms 
occurring in all patients. Choreoathetotiform movements, opisthotonus and 
selfdestructive behavior have been found in a lot of the patients but not 
in all. 
Our patients (C! and Co) show a clinical picture which can hardly be 
recognized as the Lesch-Nyhan Syndrome in spite of the biochemical ab-
normalities consisting of hyperuricemia, completely deficient HGPRT-ac-
tivity and disturbed nucleotide pattern in the erythrocytes. 
On the other hand, Benke and Herrick (1972) and Etienne et al. (1973) 
reported each one patient with the typical symptomatology of the Lesch-
Nyhan Syndrome and overproduction of uric acid but with a quite normal 
HGPRT-activity. So, it appears to be necessary to perform an assay of 
HGPRT-activity in erythrocytes of each patient with hyperuricemia inde-
pendently of the clinical features or e\en sex (see 1.1.9. )of the patient. Fur-
thermore, the performance of uric acid assay in the serum has to be part of 
the routine investigations in all patients with one of the following symptoms: 
hypotonia and developmental retardation in the young infant, spasticity of 
the limbs, unvoluntary choreoathetotiform movements, opisthotonus, dys-
phagia, dysarthria, selfdestructive behavior, renal dysfunction, anemia, and 
convulsions. 
Another aspect revealed by the present investigation is the fact that it 
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should bc doubted whether HGPRT-deficiency is causally related to the 
symptoms mostly found in Lcsch-Nyhan patients. This appears obviously 
from our investigation since the patients without any detectable H G P R T -
activity (Cj and C2) show a more mild clinical picture as compared to the 
other patients (А,, Λ2 and B) with a remaining HGPRT-activity but with 
the severe typical symptoms belonging to the Lesch-Nyhan Syndrome. 
An essential part of the biochemical investigation consisted of the assay 
of the purine nucleotides in erythrocytes in HGPRT-deficiency. The unex­
pected finding of normal or even increased concentrations of guanine nu­
cleotides and decreased concentrations of adenine nucleotides in erythro­
cytes of HGPRT-deficient individuals justified further investigations in 
order to obtain an explanation for this highly remarkable finding. 
As a hypothesis a shift from the adenine nucleotidcb towards guanine 
nucleotides was postulated. However, this shift could not explain the in­
creased concentrations of guanine nucleotides in the patients C ! and C2, as 
far as this shift was considered as a disturbance of the equilibrium between 
the monophosphoribonucleotides. T h e finding of the increased activity of 
I M P dehydrogenase in patients with HGPRT-deficiency was very important 
since the afore mentioned shift fitted to the increased I M P dehydrogenase 
activity. It is worthwhile to perform a comprehensive investigation with 
respect to I M P dehydrogenase because of the different behavior of the 
patients' enzymes towards inhibition by 2.3 D P G suggesting possibly a 
second genetic mutation in those patients besides of the HGPRT-deficiency. 
As concerning to the enzymic deficiency in our patients it appeared from 
this investigation that reports on remaining enzymic activities in inborn 
errors of metabolism should be taken very carefully since the result of enzyme 
assays strongly depends on the method used. This might be excellently 
demonstrated as far as concerning H G P R T in our 5 patients. Using the 
method of Cartier and Harnet (1968) none of the patients showed any 
HGPRT-activity, whereas distinct remaining activities of this enzyme had 
been detected in erythrocytes of the patients Ai, AL> and В but not in the 
other two patients (C, and Сч), using the method of Harris and Cook 
(1969). 
It should be kept in mind that comparison of patients suffering from an 
inborn error of metabolism as to the remaining enzymic activity is only 
useful if the same method of assay under standardized conditions has been 
used. It is very important to develop extremely sensitive methods in order 
to have the opportunity to study the properties of the mutant enzymes to 
deepen out our knowledge of the metabolic disorders. O u r observation that 
the patients with „absolute" deficiency of H G P R T show a more mild clinical 
picture as compared to the typical Lesch-Nyhan patients with a remaining 
enzymic activity demonstrates that the correlation between biochemical and 
clinical features still remains a mystery. To obtain more information about 
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this relationship it is of utmost importance to study in detail the disturbed 
purine metabolism in patients with IIGPRT-defiriency. Only a very com­
prehensive stock-taking of eventual differences in the purine metabolism 
and clinical symptoms between various patients may lead to an understand­
ing of the relationship between biochemical and clinical features. 
Furthermore, from the hopeful results of behavior-therapeutic treatment 
as concerning to the selfdestructive behavior in patient Λ2 (see 2.1.2.) it has 
to be concluded that there is no basis for the fatalist attitude of a lot of authors 
with respect to this symptom. In a multidisciplinary treatment with coopera­
tion of behavior-therapeutists, physiotherapeutists. physicians and pharma­
cologists this bizarre behavior may possibly be brought under control or 
ameliorated. 
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S U M M A R Y 
Chapter 1 deals with a review from the literature of the clinical and 
biochemical features of patients with a severe deficiency of H G P R T . 
In 1.1. a review is given of 61 patients as concerning to the clinical symp­
toms: early retardation, hypotonia, spasticity, dysphagia, dysarthria, choreo-
athetotiform movements, opisthotonus, sclfdestructive behavior, renal dys­
function, gouty arthritis and tophi, anemia and convulsions. From this 
review it is concluded that the only obligatory symptoms arc early retarda­
tion, hypotonia and spasticity. All other symptoms can be absent in more 
or less cases. Furthermore, it is established that the most striking symptoms 
of the Lesch-Nyhan Syndrome namely the chorcoathetotiform movements 
and the sclfdestructive behavior can occur independently from each other. 
The heredity and therapy of the HGPRT-deficiency is discussed concisely. 
In 1.2. a review from the literature is given of the biochemical features in 
patients with HGPRT-deficiency. After a synopsis of the normal purine 
metabolism, the aberrations in HGPRT-deficiency are discussed as con­
cerning to the enzymic deficiency itself, the purine nucleotide synthesis de 
novo and the interconversion of purine derivatives. 
In 1.3. several hypotheses as concerning to the eventual relationship 
between biochemical and clinical features of the HGPRT-deficiency are 
discussed. 
The first chapter is closed with a description of the scope and purpose 
of the present investigation. 
Chapter 2 deals with a review of the clinical features of 5 own patients 
with HGPRT-deficiency which can be divided clinically and biochemically 
in two different groups. One group consisting of the two brothers A, and 
Ач and the unrelated patient В shows the typical symptomatology of the 
Lesch-Nyhan Syndrome: hyperuricemia, hyperuricuria, developmental retar­
dation, chorcoathetotiform movements, dysarthria, dysphagia and sclfde­
structive behavior. These 3 patients showed a very low but definite re­
maining HGPRT-activity in their erythrocytes. The second group of patients, 
consisting of patient Cj and his maternal uncle Co has a more mild symp­
tomatology with slight spasticity of the legs, dysarthria and mental retarda­
tion but without choreoathetosis or sclfdestructive behavior. In these pa­
tients' erythrocytes no activity of H G P R T is detectable. 
Chapter 3 gives a report of the biochemical investigations in the afore 
mentioned 5 patients. 
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In 3.1. the material and methods used in these investigations are reported. 
The results are reported and discussed in 3.2. 
We investigated the purine nucleotide concentrations in the erythrocytes 
of the patients. Moreover, in the patients A ^ A;) and В the influence of 
adenine therapy on these concentrations has been investigated. T h e finding 
of a disturbed nucleotide pattern consisting of decreased adenine nucleotide 
concentrations and normal or even increased guanine nucleotide concentra­
tions is discussed comprehensively (З.2.1.). 
A brief report is given of the findings of the measurement of the purine 
synthesis de novo in fibroblasts from patient C
x
 and the influence of some 
purine bases on this synthesis as compared to fibroblasts from normal indi­
viduals. These investigations reveal that there is no significant difference 
in the purine synthesis de novo between fibroblasts of a patient without the 
typical symptomatology of the Lesch-Nyhan Sydrome and the synthesis in 
the fibroblasts of typical Lesch-Nyhan patients (Rosenbloom et al., 1968 a 
and b) (3.2.2.). 
In 3.2.3. the results of H G P R T and A P R T assays are reported and dis­
cussed. In the patients A] . Ao and В a very low remaining HGPRT-activity 
is found in the erythrocytes whereas the erythrocytes of the patients Ci and 
C2 show no activity at all. The APRT-activity is increased in all 5 patients 
as compared to normal individuals. 
T h e result of the assay of I M P dehydrogenase activity in erythrocytes 
of the patients as compared to normal ones is given in 3.2.4. It appears that 
I M P dehydrogenase obtained from normal erythrocytes is strongly inhibited 
by 2,3 D P G in contrast to the enzyme obtained from HGPRT-deficient 
erythrocytes which appears to be insensitive to this inhibition. No difference 
with respect to this inhibition was found between the two groups of patients. 
In 3.2.5. the results of AMP deaminase assay in erythrocytes of 3 patients 
are reported. In 2 patients the activity of this enzyme is found to be within 
normal ranges during treatment. One patient shows an increased activity 
during treatment. In patient C, we were able to establish the A M P deami­
nase activity in erythrocytes before the treatment. In that case we found 
an increased enzymic activity. 
No differences between adenosine deaminase activities in erythrocytes of 
patients and normal individuals could be established (3.2.6.). 
Finally in 3.2.7. the measurement of the purine synthesis de novo in vivo 
in patient C ! is reported. The findings in this patient are similarly to those 
in patients A ! and A..¿ as reported by van der Zee (1972). 
Chapter 4 deals with a general discussion and conclusion. 
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SAMENVATTING 
In Hoofdstuk 1 wordt een overzicht gegeven van de klinische en bioche-
mische aspecten van patiënten met een ernstige HGPRT-deficiéntie, aan de 
hand van gegevens uit de literatuur. 
In 1.1. wordt een overzicht gegeven van 61 patiënten, met betrekking tot 
de volgende symptomen: vroege retardatie, hypotonie, spasticiteit, dysphagie, 
dysarthrie, choreoathetotiforme nevenbewegingen, opisthotonus, autoplectie, 
nierfunctiestoornissen, jicht-arthritis, tophi, anaemie en convulsies. Uit dit 
overzicht wordt duidelijk dat alleen de vroege retardatie, de hypotonie en de 
spasticiteit als obligate symptomen mogen worden beschouwd. Alle andere 
symptomen kunnen in enkele of meerdere gevallen ontbreken. Voorts blijkt 
dat de meest opvallende symptomen van het Lesch-Nyhan Syndroom, name-
lijk de choreoathetotiforme nevenbewegingen en de autoplectie onafhan-
kelijk van elkaar kunnen voorkomen. Ook de erfgang en de therapie van 
de HGPRT-deficiëntie worden beknopt besproken. 
In 1.2. wordt een literatuur-overzicht gegeven van de biochemische as-
pecten van de HGPRT-deficiëntie. Na een bespreking van het normale 
purine metabolisme worden de biochemische afwijkingen bij HGPRT-defi-
ciëntie besproken, voor zover het betreft de enzym deficiëntie zelf, de purine 
synthese de novo en de interconversie van de purine derivaten. 
Een bespreking van enkele hypothesen omtrent de eventuele relatie tussen 
biochemische en klinische aspecten van de HGPRT-deficiëntie volgt in 1.3. 
Hoofdstuk 1 wordt besloten met een beschrijving van het doel en de opzet 
van het onderhavige onderzoek. 
In Hoofdstuk 2 volgt een overzicht van de klinische gegevens van 5 pa-
tiënten met HGPRT-deficiëntie, welke patiënten klinisch en biochemisch 
verdeeld kunnen worden in 2 groepen. Een groep, bestaande uit de twee 
broertjes A1 en Ao en de niet verwante patiënt B. vertoont de typische 
Symptomatologie van het Lesch-Nyhan Syndroom: hyperuricaemie, hyper-
uricurie, ontwikkelingsachterstand, choreoathetotiforme nevenbewegingen, 
dysarthrie, dysphagie en autoplectie. Deze 3 patiënten hebben een zeer lage 
maar duidelijk aantoonbare rest HGPRT-activiteit in hun erythrocyten. De 
tweede groep patiënten, bestaande uit patiënt Ci en zijn oom van moeders-
zijde C^, vertonen een minder ernstig klinisch beeld met lichte spasticiteit 
van de benen, dysarthrie en lichte debilitas mentis doch zonder choreoathe-
tosc of autoplectie. In de erythrocyten van deze patiënten is geen rest activi-
teit van H G P R T aantoonbaar. 
Hoofdstuk 3 geeft een overzicht van de biochemische onderzoekingen bij 
de hiervoor genoemde 5 patiënten. 
In 3.1. worden de materialen en methoden beschreven die bij deze onder-
zoekingen gebruikt zijn. De resultaten worden beschreven en besproken 
in 3.2. 
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Wij onderzochten de purine nucleotiden concentralies in de erythrocyten 
van de patiënten. Bij de patiënten A·], Ao en В werd tevens de invloed van 
adenine therapie op deze concentraties nagegaan. De bevinding van een 
verstoord nucleotiden patroon bestaande uit een verlaging van de adenine 
nucleotiden concentraties en normale of zelfs verhoogde guanine nucleotiden 
concentraties wordt uitgebreid besproken (З.2.1.). 
Een kort verslag wordt gegeven van de metingen van de purine synthese 
de novo in fibroblastcn van patiënt G| en van de invloed van enkele purine 
basen op deze synthese, in vergelijking met normale fibroblastcn. Deze 
onderzoekingen brengen aan het licht dat er geen wezenlijk verschil is tussen 
de purine synthese de novo in fibroblastcn van een patiënt zonder de typische 
Symptomatologie van het Lesch-Nyhan Syndroom en de synthese in fibro-
blasten van typische Lesch-Nyhan patiënten (Rosenbloom et al., 1968 a 
and b) (3.2.2.). 
In 3.2.3. worden de resultaten van de H G P R T en APRT metingen ge-
rapporteerd en besproken. Bij de patiënten A j . A.j en В wordt een lage rest 
activiteit van H G P R T gevonden in de erythrocyten, terwijl bij de patiënten 
C, en C;) geen activiteit gevonden wordt. De APRT-activiteit is bij alle 
5 patiënten verhoogd. 
De resultaten van de I M P dehydrogenase activitcitsmetingen in erythro-
cyten van de patiënten in vergelijking met normale individuen worden be-
schreven in 3.2.4. Het blijkt dat I M P dehydrogenase verkregen uit nor-
male erythrocyten sterk geremd wordt door 2.3 DPG in tegenstelling tot het 
enzym uit HGPRT-deficiënte erythrocyten, dat ongevoelig blijkt te zijn voor 
deze remming. Wat deze remming betreft wordt er geen verschil gevonden 
tussen de 2 groepen patiënten onderling. 
In 3.2.5. worden de resultaten beschreven van de metingen van de AMP 
deaminase activiteit in erythrocyten van 3 patiënten. Gedurende therapie 
worden voor 2 patiënten normale waarden gevonden. Een patiënt vertoont 
een verhoogde activiteit tijdens therapie. Bij patiënt C] was het mogelijk 
de AMP deaminase activiteit ook te meten vóór behandeling. In dat geval 
wordt een verhoogde enzym activiteit gevonden. 
Er worden geen verschillen gevonden tussen de activiteiten van adenosine 
deaminase in erythrocyten van patiënten en normale individuen ( 3.2.6. ). 
Tenslotte wordt in 3.2.7. een verslag gegeven van de metingen van de 
purine synthese de novo in vivo bij patiënt C ^ De bevindingen zijn in over-
eenstemming met de bevindingen van van der Zee (1972) bij de patiënten 
A} en Ao. 
In Hoofdstuk 4 wordt een algemene slotbeschouwing en conclusie gegeven. 
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C U R R I C U L U M П А Е 
De auteur van dit proefschrift werd geboren op 20 februari 1941 te Bocholtz 
In 1959 heeft hij het eindexamen HBSb afgelegd aan de R К HBS St Antonius Dr 
te Kerkrade Hierna studeerde hij geneeskunde aan de Katholieke Universiteit te 
Nijmegen Hij legde het doctoraalexamen af in oktober 1965 en het artsexamen in 
oktober 1967 Na een korte periode als wetenschappelijk medewerker weikzaam te 
zijn geweest op de afdeling Biochemie van deze universiteit begon hij in mei 1968, 
eveneens in Nijmegen, op de afdeling Paediatne, met de opleiding tot kinderarts, 
welke m mei 1972 werd voltooid Sindsdien was de auteur op dezelfde afdeling 
werkzaam aan een door de stichting Medisch Wetenschappelijk Onderzoek „ F U N G O " 
gesubsidieerd project 
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STELLINGEN 
1. De in de literatuur ten toon gespreide fatalistische houding ten aanzien 
van de autoplectie bij patiënten met het Lesch-Nyhan Syndroom is 
ongegrond. 
2. Het is niet uitgesloten dat de gcdragsverbetering van één patiënt met 
het Lesch-Nyhan Syndroom die Nissim et al. menen te zien tengevolge 
van adeninetherapie, in feite het resultaat is van een verbeterde ver-
pleging en verzorging van de patient. 
S. Nissim et al, (19731 International Symposium on Purine 
Metabolism m Man Isr J Med Sci , 9 . 28. 
3. De detecticgrens van de hypoxanthine-guanine phosphoribosyltransfcrase 
bepaling zoals opgegeven door Nyhan is onwaarschijnlijk laag. 
W L Nyhan (1968) Fed Proc , 27 1034. 
4. Het hoge gehalte aan HbF in neonatale crythrocyten kan mogelijk een 
verklaring vormen voor het relatief zeldzaam voorkomen van ernstige 
icterus neonatorum bij kinderen met congenitale sferocytose 
V. Izrael, (1472) Actualités Hématologiques, sixième serie 
Ed Mdsson Cie, Paris. 
5. Er zijn duidelijke aanwijzingen dat het mogelijk is door het toedienen 
van extra zuurstof aan prematuur geboren kinderen, de sluiting van de 
ductus Botalli te bespoedigen. Mogelijk kan op deze wijze een operatic 
vermeden worden. 
Ρ M Dunn and В D Speidel, (1973) Lancet, II : 333 
6. De conclusie van Beadmore et a l , dat allopurinol en oxypurinol in vitro 
een activerende werking uitoefenen op orotzuur phosphoribosyltrans-
ferase en orotidine monophosphaat decarboxylase in crythrocyten, is 
onvoldoende gefundeerd 
Th D Beardmore et al, (1972). J Clin Invest, 51 -1823 
7 Alvorens over te gaan tot het sluiten van een ventrikel septum defect 
bij kinderen, die tevoren een ,.banding" van de arteria pulmonalis 
hebben ondergaan, dient een musculaire sténose van het uilstroomgebied 
van de linker kamer uitgesloten te worden. 
M D Freed et al, (1973). Circulation, 48, suppl III -7 

8. De behandeling van hypophysaire diabetes insipidus met DDAVP biedt 
belangrijke voordelen in vergelijking met de behandeling met vaso-
ргеььіпе. 
A. S. Aronson et al., (1973): Acta Paediat. Scand., 62 : 133. 
9. De gezondheidszorg in Nederland kan pas dan goed worden gerealiseerd 
wanneer medische, psychologische en maatschappelijke hulpverlening 
gecoördineerd verleend kunnen worden vanuit gezondheidscentra die 
door een volksverzekering worden gefinancierd. 
10. Uit de definitie van een attractant zoals gegeven door Mezibov en Adler 
moet worden geconcludeerd dat zij beschikken over /eer nauwkeurige 
analysetechnieken voor aminozuren. Dit is echter niet in overeenstem-
ming met de door hun beschreven methodieken. 
R. Mezibov and J. Adler, (1972): J. Bacleriol., 112 : 315. 
11. De witte ANWB-wegwijzers leveren een gevaar op voor de verkeers-
veiligheid en dienen derhalve vervangen te worden door de blauwe 
ANWB-wegwijzers. 
12. ,,Wenn das Wasser im Rhein goldner Wein wäre" zou het toch niet te 
drinken zijn. 
E. J. P. Lommen - 21 december 1973. 



